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Regulatory T cells, a subpopulation of suppressive T cells, are potent mediators
of self-tolerance and essential for the suppression of triggered immune responses.
The immune modulating capacity of these cells play a major role in both
transplantation, autoimmune disease, allergy, cancer and pregnancy. During pregnancy,
low numbers of regulatory T cells are associated with pregnancy failure and pregnancy
complications such as pre-eclampsia. On the other hand, in cancer, low numbers
of immunosuppressive T cells are correlated with better prognosis. Hence, maternal
immune tolerance toward the fetus during pregnancy and the escape from host
immunosurveillance by cancer seem to be based on similar immunological mechanisms
being highly dependent on the balance between immune activation and suppression.
As regulatory T cells hold a crucial role in several biological processes, they may also
be promising subjects for therapeutic use. Especially in the field of cancer, cell therapy
and checkpoint inhibitors have demonstrated that immune-based therapies have a
very promising potential in treatment of human malignancies. However, these therapies
are often accompanied by adverse autoimmune side effects. Therefore, expanding
the knowledge to recognize the complexities of immune regulation pathways shared
across different immunological scenarios is extremely important in order to improve and
develop new strategies for immune-based therapy. The intent of this review is to highlight
the functional characteristics of regulatory T cells in the context of mechanisms of
immune regulation in pregnancy and cancer, and howmanipulation of these mechanisms
potentially may improve therapeutic options.
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INTRODUCTION
Regulatory T cells (Tregs) constitute a dynamic and diverse T cell population composed of several
subsets distinguished by phenotypic and functional characteristics. With their immunosuppressive
properties, Tregs are central to the maintenance of immune homeostasis. They are implicated
in critical immunoregulatory functions in several physiological conditions such as inflammatory
responses, tissue repair, and reproduction. Furthermore, Tregs also play an important role in the
pathophysiological immune tolerance induced by tumors (1–4). Hence, selective immunological
tolerance is essential during any of these processes, and the mechanisms by which immune
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tolerance is sustained by Tregs might be similar. Some of the
mechanisms responsible for induction of maternal immune
tolerance during pregnancy may be the same as those involved
in controlling an inflammatory response from not exaggerating
beyond control, and furthermore the same mechanisms that
may provide a pro-tumorigenic environment which allows
cancer development. The role of Tregs is somewhat opposing
in relation to a role in protecting the body and preventing
disease development. Tregs must allow protective immune
responses against pathogens and tumors, but simultaneously
prevent inflammatory diseases by restraining aberrant responses
to self and innocuous antigens with pregnancy as a borderline
condition, where Tregs contribute to the establishment of active
immune tolerance toward the fetus (Figure 1).
The similarities between reproductive biology and cancer
development in terms of immunology is not that implausible.
During pregnancy, the formation of the placenta involves the
invasion of the semi-allogeneic fetal trophoblast cells into the
maternal tissue for anchoring and vascular adaptions, such
as formation of spiral arteries providing nutritional support
for the growing fetus. The maternal immune system has to
allow this invasion of partly foreign cells to ensure a successful
pregnancy. Thus, cancer cells and cells of the developing placenta
both share the capacity to invade normal tissue and create
a microenvironment that support immunologic privilege and
angiogenesis (Figure 1). The proliferation and migration of
cancer cells at a distant site mediated in part by modulation of
a tolerogenic immune response in the tumor microenvironment
may be compared to the situation in pregnancy, in which the
developing placenta invades the uterus and a semi-allogenic
fetus escapes rejection from the maternal immune system (5–
7). A prominent hypothesis states that the failure to establish
immune tolerance during pregnancy may lead to pregnancy
complications or pregnancy loss. However, this may indicate that
it should be possible to exploit the same mechanisms responsible
for immune regulation during pregnancy in treatment of cancer
and to reject cancer cells by immunological mechanisms (5).
Finally, it is important to remember that immunomodulation
and immunosuppression during pregnancy are physiological
mechanisms but in cases of cancer they are pathological and in
most cases unfavorable.
The function of Tregs as potent anti-inflammatory cells
has led to considerable interest in their therapeutic potential.
In cancer, there has been much progress within the field of
immunotherapy within the last decade. Especially, cancer therapy
by inhibition of negative immune regulation is already used
in the clinic. Manipulation and propagation of Tregs and their
therapeutic application is a promising approach in order to reach
a clinical benefit for affected patients (8–10).
As brieflymentioned above, while pregnancy is a physiological
process in which the presence of Treg cells is favorable, cancer
is a pathophysiological scenario in which the suppression of a
potential anti-tumor response is undesirable. However, as will
be discussed in later sections, this distinction is not always
obvious, and in some cancer settings, the presence of Treg
cells and thus the control of the inflammatory environment can
probably be advantageous seen from an anti-tumor perspective.
FIGURE 1 | Immune mechanisms during pregnancy and cancer development.
Although immunomodulation during pregnancy is a physiological process and
in cases of cancer a pathophysiological process, there are a number of
similarities in cellular and molecular mechanisms at the feto-maternal interface
and in the tumor microenvironment. Tumors and fetuses seem to exploit some
of the same immunomodulating mechanisms. Formation of the placenta
during pregnancy involves invasion of fetal trophoblast cells into the maternal
tissue for anchoring and vascular adaptions. In cancer, local invasion into
neighboring tissue is essential for manifestation of malignant growth and the
first stage in development of secondary tumors or metastases. Furthermore,
several immune cells are present both at the feto-maternal interface and in the
tumor microenvironment, here with malignant melanoma as an example. There
is increasing evidence that regulatory T cells play important roles both in
cancer and in reproduction. [Illustration partly inspired by Holtan et al. (5)].
This highlights the importance of broadening our understanding
of the function of Treg cells across different physiological
and pathophysiological settings, such as pregnancy, pregnancy
complications, and cancer, in order to develop and offer the
right therapeutic treatment. This review provides an overview
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of current knowledge on the tolerogenic function of Tregs in
immunological mechanisms during pregnancy and cancer, and
in relation to possible therapeutic intervention of both human
malignancies and reproduction.
REGULATORY T CELLS
Regulatory T cells are a T lymphocyte population with
immune suppressive properties responsible for maintaining
antigen-specific T cell tolerance. Tregs comprise both
CD4+ and CD8+ subtypes. Whereas, CD4+ Treg cells
have been extensively studied, lack of clear markers to
distinguish CD8+ Tregs from conventional CD8+ T cells
has led to unsatisfactory characterization of origin, function
and phenotype (11, 12). Therefore, this review will focus
mainly on CD4+ regulatory T cell subsets, and “Treg” or
“regulatory T cell” will refer to CD4+ regulatory T cells, unless
stated otherwise.
Normally, CD4+ Tregs constitute 5–10% of the total CD4+
T cell population and are derived from thymic precursors (13).
Regulatory T cells where first described in 1972, where Gershon
et al. showed that T cells were capable of suppressing the antigen-
induced response of other T cells directly without the mediation
of B cells and their production of antibodies (14). However, it was
not until 1995 that Tregs were identified as a specialized CD4+
T cell population expressing CD25 (15). Subsequently, several
in vitro studies showed that CD4+CD25+ T cells represent
a distinct lineage of naturally anergic and suppressive cells
(16, 17). The original studies on characterization of Tregs
were performed in mice. However, in 2001 a T cell population
with identical immunosuppressive properties was identified in
humans (18–21). In 2003, the transcription factor forkhead
box protein P3 (FoxP3) was identified as a potent marker for
Tregs in several mouse studies. FoxP3 deficiency caused a fatal
lymphoproliferative disease demonstrating that the transcription
factor was essential for development of Tregs and for their
immunosuppressive function (22–24). The requirement of FoxP3
expression for immunosuppression was later demonstrated in
humans (25).
Based on these discoveries, expression of CD25 on the cell
surface and presence of the intracellular transcription factor
FoxP3 became the key characteristics of the Treg population.
The mutual expression of these markers is commonly used for
identification of Tregs in experimental settings. Conversely, some
studies suggest a lack of correlation between CD25 and FoxP3 in
human and mice CD4+ T cells (24, 26). Alternatively, Liu et al.
found that low expression of CD127 serves as a good biomarker
for human Tregs together with CD25 expression (26), although
other studies have not been able to find a clear correlation
between CD127lo and FoxP3 expression (27). In addition, several
sub-populations of CD4+CD25−FoxP3− Tregs have also been
identified (28). Hence, the most specific marker still remains
a matter of debate. Nevertheless, as expression of FoxP3 has
been shown to correlate with suppressor activity irrespectively of
CD25 expression many consider FoxP3 as the most specific Treg
marker (29).
Regulatory T Cell Subsets
Tregs are found throughout the body, where they modulate
activities of cellular components of both the innate and adaptive
immune system. CD4+ Tregs can be divided into distinct subsets
according to unique functional and homeostatic properties
(Figure 2). FoxP3+ Tregs originating from the thymus, where
they have differentiated during T cell ontogenesis, are referred
to as natural or thymic (t) Tregs, and Tregs developed in the
periphery or in vitro from conventional CD4+ T cells are referred
to as peripheral or induced (i) Tregs (30, 31). Furthermore, there
are two phenotypically distinct immunosuppressive subtypes
of the iTregs, namely the IL-10 producing T regulatory type
1 (Tr1) cells and the TGF-β-producing Th3 cells (32, 33). It
remains to be determined, whether the different subsets of Tregs
belong to unique cell lineages, or whether they only reflect the
plasticity of the Treg population and represent an altered state
of differentiation (34). Furthermore, it is debated, whether iTregs
can arise from any conventional T cell or from a pre-committed
cell lineage (35).
Both tymus-derived tTregs and peripheral iTregs
are characterized by high expression of CD25, FoxP3,
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and
glucocorticoid-induced tumor necrosis factor-related receptor
(GITR), but iTregs have been shown to express reduced levels of
programmed cell death protein 1 (PD-1), CD73, the transcription
factor Helios and the surface antigen neutropilin-1 (Nrp1) (36).
Both Helios and Nrp1 have been suggested as markers for
distinguishing between tTregs and iTregs, but the specificity
of these markers is a current matter of debate (36–39). Mice
studies have suggested that GITR is involved in the generation
and maturation of FoxP3+ tTregs and Tr1-like cells (40, 41).
Furthermore, it has been suggested that GITR is a marker of
active Tregs (42). In addition to the above mentioned markers,
expression of the ATP-degrading enzymes CD39 and CD73 on
the surface of Tregs have been increasingly used as markers of
Tregs and might contribute to the suppressive activity together
with expression of the immunoglobulin-like transmembrane
protein LAG3 (Figure 3) (43–46).
Thymic CD4+CD25+ tTregs are developed in the thymus
from CD4+ precursors. Development of tTregs or conventional
CD4+ T cell populations from the CD4+ precursor depends
on the affinity of the T cell receptor (TCR) for self-antigens:
low affinity leads to positive selection of conventional CD4+ T
cells, whereas medium affinity interactions with thymic epithelial
cells lead to development of CD4+CD25+ tTregs (47–49).
Immunosuppression by tTregs require activation via their TCR.
When activated, the suppressor effector function is independent
of antigen-specificity. Conversely, inhibition of the effector T
(Teff) cell population is mainly depending on cell contact and
independent of suppressive cytokines (18, 50). The result of tTreg
mediated immune regulation is reduced number of Teff cells and
altered activity and trafficking pattern of activated Teff cells (37).
In vitro or in vivo induced iTregs can be differentiated from
naïve CD4+ T cells in response to antigen, CD28, TGF-β and
IL-2 stimulation, and mediate their suppressive activity mainly
via secretion of cytokines such as IL-10 and TGF-β that reduce
the capacity of dendritic cells (DCs) to present antigen (37).
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FIGURE 2 | Characteristics of CD4+ regulatory T cell subsets. Different subsets of CD4+ regulatory T (Treg) cells exist and play a role in the establishment of
tolerance in different physiological and pathophysiological settings. Thymic (t)Tregs and HLA-G+ Tregs are developed in the thymus in response to self-antigen,
whereas induced (i)Tregs, Tr1 cells and Th3 cells are developed in the periphery in response to antigen presentation and cytokines. Natural Treg and iTregs are
characterized by CD25 and FoxP3 expression, while HLA-G+ Tregs, Tr1, and Th3 cells are CD25−FoxP3−, although controversies do exist (see the text for details).
The thymus-derived Treg cells mediate their effect mainly through cell contact. In contrast, immune suppression by peripheral induced iTreg, Tr1, and Th3 cells are
mediated mainly via secretion of the anti-inflammatory cytokines TGF-β and IL-10.
As for the iTregs, the peripheral Tr1 and Th3 subsets are also
induced in the periphery from the conventional CD4+ T cells.
In contrast to tTregs and iTregs, expression of CD25 and FoxP3
in Tr1 and Th3 cells are controversial (51–53). Tr1 and Th3
have been identified as FoxP3- and CD25-negative, although it
seems that expression of both markers can be upregulated in
response to activation (53, 54). The Tr1 cells were first described
by Groux et al. (55), who found that Tr1 cells are activated by
IL-10 and suppress the proliferation of CD4+ cells in response to
antigen (55). Presence of IFN-α further enhances IL-10-mediated
induction of Tr1 activation and differentiation (56). The Tr1
cells constitute a low proliferating subset that produces high
levels of IL-10, low levels of TGF-β and marginal or no IL-2 and
IL-4 (55, 57). Th3 cells are activated upon antigen stimulation
(58). However, TGF-β also promote the induction of Th3 cells
from CD4+ T cells, which can be further enhanced by the
presence of IL-10 and IL-4 (32). When active, the Th3 cells have
suppressive properties for Th1 and Th2 cells through secretion of
TGF-β (59, 60).
A new subset of regulatory T cells have emerged during the
recent years defined by expression of the immunosuppressive
Human Leukocyte Antigen (HLA) molecule HLA-G (Figure 2).
In 2007, Feger et al. identified HLA-G+ T cells among CD4 and
CD8 single-positive cells in the peripheral blood and thymus
from healthy individuals (61). The cell population showed
reduced proliferation to allogeneic and polyclonal stimuli and
the suppressive effect of HLA-G expression was confirmed
by neutralization of HLA-G on CD4+HLA-G+ cells, which
reduced their suppressive capacity. The cells were, however, not
expressing CD25 and FoxP3, like previously described Tregs.
When comparing the properties and molecular characteristics
of CD4+HLA-G+ cells and CD4+CD25+FoxP3+ cells, there
is a clear distinction between the phenotype and the cytokine
profile of the two cell populations (62). The suppressive function
of CD4+HLA-G+ cells is mediated mainly by secretion of
soluble HLA-G and high levels of IL-10 and IL-35, while
CD4+CD25+FoxP3+ cells seems to workmainly in a cell-contact
dependentmanner. Furthermore, CD4+HLA-G+ cells are clearly
distinct from Tr1 cells as they do not require the presence
of other cell types (63). The identification of a novel T cell
population with regulatory properties expressing HLA-G on the
surface has led to the notion of a new subset belonging to the
repertoire of suppressor T cells (64). As these cells have a similar
function as CD4+CD25+FoxP3+ Tregs, their role in peripheral
immune regulation is increasingly recognized. However, whether
they should be identified as traditional regulatory T cells as the
classical Tregs is somehow controversial.
No universal agreement on which factors that can be used
to differentiate tTregs from iTregs seems to exist. Moreover,
it is important to note that most studies have used shared
markers such as FoxP3, CD25, and CD127 for identification of
Treg cells, thus do not differentiate between tTregs and iTregs,
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FIGURE 3 | Schematic overview of similarities in Treg function in central tolerance, fetal tolerance, and cancer tolerance. Tolerance play an important role in both fetal
and cancer tolerance. Tregs are developed by presentation of antigens of fetal (fAg) or tumor (tAg) origin. Many tumor cells and fetal extravillous trophoblast (EVT) cells
have both diminished or no expression of MHC class II and classical MHC class I molecules. Instead, the EVT cells and some cancer cells express HLA class Ib
molecules, e.g., the immune modulatory non-classical HLA-G. HLA-G is able to protect fetal and tumor cells from NK cell lysis, as well as according to a few studies
to induce Treg formation. Fetal EVTs and tumor cells are also able to contribute to Treg homeostasis by inhibiting effector T cell activation and proliferation through
PD-L1/PD-1 and indoleamine-2,3-dioxygenase (IDO) expression. Decidual (d)NK cells further contribute by inhibiting Th17 responses by IFN-γ expression. Fetal EVTs
also express cytokines, e.g., IL-10 and TGF-β that induce Treg development. Tregs limit Teff cells and promote their own proliferation and survival through direct
engagement with Teff cells, e.g., via PD-L1/PD-1, by the conversion of ATP to Adenosine (Ado) and cytokine secretion.
and by that definition also exclude any immunosuppressive
FoxP3− T cells, such as the Tr1, Th3, and HLA-G+ Tregs.
The following section will focus on studies using FoxP3,
CD25, and CD127, and the term “Treg” will therefore refer to
regulatory CD4+ T cells regardless of origin, unless specifically
stated otherwise.
THE ROLE OF TREGS IN CANCER
The progression of cancer is controlled by a complex biologic
system that is highly dependent on interaction between the
malignant cells and the surrounding tumor microenvironment
comprising the immune cells. Various types of immune cells
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can infiltrate the tumor and may influence tumors differently
depending on their histological and molecular type, their stage,
the microenvironment of the organ in which they occur, and
the nature of the tumor (Figure 1) (65). Immune effector
cells can detect and destroy cancer cells preventing tumor
formation by means of both the innate and adaptive immune
compartments. However, the anti-tumor activity of the immune
cells are often downregulated by tumor-derived signals leading
to immune escape. A large number of preclinical models
have demonstrated the influence of Tregs in development and
progression of several types of malignancies, and Tregs are
generally believed to be a significant contributor to tumor
immune escape (66, 67). A widely accepted hypothesis is that
recruitment of tumor-infiltrating Tregs with immunosuppressive
properties enable the malignant cells to evade the host immune
response (68).
Increased numbers of tumor-infiltrating Tregs have
been demonstrated in patients with ovarian (69), liver (70),
melanoma (68), gastric, and esophageal cancer (71), in
chronic lymphocytic leukemia (72), and in breast cancer,
where it is associated with a more aggressive phenotype
(73). The same is seen in gastric and esophageal cancers,
where Tregs increase with disease stage suggesting induced
expansion of Tregs by tumor-related factors (74). Furthermore,
Treg numbers are also increased in the peripheral blood
of patients with breast, pancreatic (75), liver (70), gastric,
and esophageal cancer (71) in comparison with blood from
healthy individuals.
Various studies have tried to identify the role of Tregs in
immune evasion, and as it has become clear that the effect
of Tregs on tumor progression vary according to the tumor
type, the prognostic significance of Treg infiltration remains a
matter of debate. An overview of the clinical significance in
a range of cancers is provided in Table 1. In connection to
the role of Tregs in evading immune recognition, a common
presumption is that high numbers of Tregs within lymphoid
infiltrates can be predictive of relapse and dead. However, the
prognostic value of Tregs is somehow controversial as in some
cancers Tregs infiltration may exert a beneficial role or can
have both a negative and positive effect on disease progression
and survival. The negative effect on survival is observed in
pancreatic (87), liver (90), gastric, and esophageal cancer (74).
It is though more likely to observe opposing roles of Tregs
in terms of survival in a wide range of cancer types such as
cases of ovarian carcinoma (69, 76), colorectal cancer (85, 86),
melanoma (88), breast cancer (77–84), head and neck squamous
cell carcinoma (91, 92), and lymphoma (93–96), where a high
frequency of Tregs improve disease-specific survival in some
patients and in others favors immune escape and tumor growth.
Furthermore, in some patients there is no correlation between
Treg infiltration and disease progression at all (89). The reason
for this discrepancy in the prognostic value of Treg infiltration
might be related to the different nature of the cancers and
the effect of inflammation on tumor growth, but could also
be dependent on the presence of different Treg subsets in the
different malignancies.
Mechanisms of Treg-Mediated
Immunosuppression in Cancer
Several mechanisms contribute to the accumulation of Tregs
within neoplastic lesions including increased infiltration,
local expansion, survival advantage, and development from
conventional CD4+ cells (30). All of these mediated through
signaling with other cells and through different signaling
molecules (Figure 3).
Studies on mice deficient of key markers of Tregs, including
IL-10, CTLA-4, GITR, or PD-1 that develop severe immune-
related disorders indicate that these molecules are crucial for
Treg function in a cancer setting. The CTLA-4 receptor is a
negative regulator of T cell responses functioning as an immune
checkpoint. Leach et al. was the first to show that blockades of
the inhibitory signals of CTLA-4 enhance antitumor immunity
in mice (97). Proof that this was also the case in humans came
in 2003 in a clinical investigation, where CTLA-4 blockade
increased tumor immunity in some previously vaccinated
melanoma and ovarian carcinoma patients (98). Much research
have been performed on the mechanism of antitumor immunity
elicited by CTLA-4 blockade and one study has shown that
Treg-specific CTLA-4 deficiency results in downregulation of
CD80 and CD86 on DCs leading to loss of immunosuppression
(99). This happens in part through abrogated expression of the
immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO)
by the DCs (100). When it comes to cancer, IDO is expressed
also within solid tumors from both tumor and stromal cells,
where it under normal conditions restrains an inflammatory
reaction against cancer cells by degradation of tryptophan and
recruitment of Tregs (101, 102). Another commonly known
checkpoint molecule is PD-1. PD-1 is a receptor expressed on
activated T cells, B cells, and myeloid cells. One of the early
proofs of PD-1 being involved in maintenance of self-tolerance
came in 1999, where a knock-out mouse model showed that a
defect in the PD-1 gene specifically predisposes to development
of lupus-like autoimmune disease suggesting that PD-1 serves
as a negative regulator of immune responses (103). The same
was seen in humans, where a study by Freeman et al. revealed
that engagement of PD-1 by its ligand PD-L1 led to inhibition of
T cell receptor-mediated lymphocyte proliferation and cytokine
secretion (104). Furthermore, blockade of PD-1 seems to enhance
recruitment of Teff cells in intrasplenic tumors and prevent
metastatic spread of several different cancers (105). The crucial
role of CTLA-4 and PD-1 in regulation of a tolerogenic immune
response opens up for a blockage of both checkpoint molecules
that may have great therapeutic potential in terms of activating
an immune response against the cancer cells. Whereas, both
CTLA-4 and PD-1 function as negative regulators, GITR function
as a co-stimulatory receptor, leading to activation, proliferation
and cytokine production in both Teff and Treg cell populations
(106–108). As mentioned, GITR is expressed in high levels by
Tregs, and has been shown to be increased in several cancer
forms including breast cancer (42, 109, 110). Engagement of
GITR on Treg cells has been shown to inhibit their suppressive
function, and rendering Teff unresponsive to Treg-mediated
suppression (106, 107). However, it has also been shown that
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GITR induces IL-10 production, that if blocked leads to further
GITR-mediated proliferation (108), leaving the exact role of
GITR controversial. As shown in a study, the function of GITR
on Treg cells is most likely context-dependent and rely on the
model used to study its function, as well as the immunological
milieu (111). Nevertheless, GITR is, like CTLA-4 and PD-1,
an attractive target for immunotherapy, and GITR triggering
using agonist antibodies and Fc-GITRL abrogates Treg-mediated
suppression (106).
Whereas, the function of tTregs is mainly cell-cell contact-
dependent, the secretion of soluble factors, such as cytokines
by iTregs and other Treg subtypes is essential for their
function (Figure 2). IL-10 is a cytokine produced by CD44hi
Tregs and plays a central role both in parasitic infections
(112), intestinal inflammation (113), and cancer (114) again
emphasizing the involvement of similar mechanisms in different
pathophysiological conditions. In addition to IL-10, TGF-β is
also produced by peripheral Tregs. Both IL-10 and TGF-β have
pleiotrophic functions and have been implicated in both cancer
progression as well as clearance [reviewed by (115)]. The effect of
IL-10 and TGF-β therefore most likely depends on the specific
cancer type, and therapy targeting these cytokines should be
done with careful considerations. Considering that Treg cells
are defined as CD25hi, the high affinity IL-2Rα chain, IL-2 is
another cytokine central to both thymic and peripheral Treg
development, function and homeostasis (116, 117). In contrast,
the IL-7 receptor α chain, CD127, is low or absent in human
Tregs, indicating that IL-7 is not required for Treg function,
although a study in mice has suggested that IL-7 might be
involved in early Treg development and in development of
CD4+FoxP3lo Tregs (116, 117).
Another increasingly acknowledged mechanism involved in
development of cancer is regulation of the expression of
HLA molecules in the tumor microenvironment. Increasing
evidence suggest that expression of the classical and non-
classical HLA class Ia (HLA-A, HLA-B, HLA-C) and class
Ib (HLA-E, HLA-F, HLA-G) molecules influence immune
regulation in a coordinated action with Tregs. This influence
of HLA molecules is seen in multiple physiological and
pathophysiological processes as the antigen-presenting capability
of HLA molecules play a crucial role in infectious diseases, graft
rejection, autoimmunity, reproduction, and cancer. Deregulation
of the HLA class I molecules on the cancer cells leads to
evasion of the host immune system (118). In a recent study
on the prognostic value of tumor-stroma ratio combined with
the immune status of the tumor, Vangangelt et al. showed that
breast cancer patients with a stroma-low tumor and expression of
classical HLA class I molecules have a better prognosis compared
to patients with a stroma-high tumor and downregulation of
HLA class I (119). Furthermore, when expression of HLA class
Ia molecules are concomitantly lost, high expression of HLA-G
is associated with a worse relapse-free period in breast cancer
(120) and is suggested to facilitate invasion and increase the
metastatic capacity of invasive ductal breast carcinoma (121–
123). In gastric cancer, HLA-G expression significantly correlates
with the presence of Tregs and is predictive of poorer survival
(124). Expression of HLA-G and the presence of FoxP3+
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tumor-infiltrating lymphocytes is also believed to contribute
to the suppression of effective T cell immune responses in
melanoma (68, 125). We have recently shown an association
between high HLA-G expression and a high frequency of FoxP3+
tumor-infiltrating lymphocytes in malignant melanoma patients
(126). Furthermore, in an in vitro study we have demonstrated
that the HLA-G+ choriocarcinoma cell line JEG-3 originating
from placenta upregulates Tregs, and that the level of pro-
inflammatory cytokines is modulated through HLA-G (127).
A subset of HLA-G-expressing T cells have also been shown to
play a role in promoting a tolerogenic tumor microenvironment.
A recent study found a population of CD4loHLA-G+ T cells
associated with development of castration-resistant prostate
cancer in prostate cancer patients after treatment with androgen
deprivation therapy. Expansion of the CD4loHLA-G+ cells
resulted in impaired immune surveillance and a tumor
microenvironment that were permissive of tumor growth (128).
In pregnancy, CD4+HLA-G+ T cells have been reported andmay
be reduced in pre-eclampsia, although knowledge of a possible
role of this subset is currently very limited (129).
We are currently investigating how expression of HLA class
Ia and Ib expression modulate the immune response in breast
cancer with emphasis on Tregs and Natural Killer (NK) cells.
By studying molecular and genetic changes of the immune
cells in contact with tumor cells we aim to identify molecular
markers associated with the regulatory function of the immune
cells and clinical outcome. Identification of regulatory immune
cell gene signatures in tumors can be important and relevant
when assessing the clinical course of the disease and prognosis.
A recent study focusing on immunogenic gene signatures in
triple-negative breast cancer found a high expression of tumor-
infiltrating lymphocyte gene signatures in the tumor compared
to normal tissues and that elevated levels of Treg gene sets
were consistently associated with better overall survival and
disease free survival (84). This confirms the controversy about the
prognostic significance of Tregs in the tumor microenvironment
and emphasizes the importance of research that can elaborate
on the role of Tregs in a specific cancer setting and for the
individual patient.
Substantial redundancy may exist in the mechanisms essential
for establishment and maintenance of immune tolerance (46).
Hence more research is necessary to identify mechanisms
that could constitute the best targets for immunotherapeutic
treatment strategies.
Antigen-Specific Tregs
With the aim to elucidate the role of Tregs in cancer
development, several studies have found that the Treg response
is an early event preceding the activation of Teff cells (130,
131). It was seen many years ago in mice, that a regulatory
immune response are present early followed by a decrease in
cellular reactivity against the tumor cells and a progressive loss
of immune recognition correlated with progression of tumor
growth (132). A mechanism by which Tregs are stimulated by the
presence of the tumor is via recognition of antigens.
Tumors are believed to present tumor-specific antigen in the
form of neo-epitopes, sometimes known as tumor-associated
antigens. Since tumor cells originate from normal cells and
develop within the context of self-tissue, most cancer antigens
are self-antigens, and the immune mechanisms that prevent
immune recognition of the tumor cells might function in similar
ways as those that prevent autoimmune attack of normal tissue
(133, 134). This is contrary to pregnancy, where both foreign
and self-antigens are present from the semi-allogenic fetus and
immune suppression is necessary in order to avoid fetal rejection.
However, it may be emphasized that cancer cells might eventually
also, due to high mutational rate, express antigens foreign to the
body that can be recognized by Teff cells.
A previous study by Wang et al. characterized tumor-specific
CD4+ T cells derived from a melanoma patient and were
the first to isolate antigen-specific Tregs, and further showed
that cell-cell contact was required for T cell-mediated immune
suppression in agreement with previous studies (135). The group
identified Tregs specific for LAGE1 and afterwards the ARCT-
1 peptide (136). Tregs specific for a broad range of tumor
antigens including melanoma tissue differentiation antigens
and cancer-testis antigen, have been identified in patients with
metastatic melanoma (137), and following studies performed
in colorectal cancer have also revealed tumor antigen-specific
Tregs (138). In colorectal cancer patients undergoing resection,
a high level of FoxP3+ Tregs specific for tumor antigens drives
immunosuppression and correlates with tumor recurrence and
relapse (139). Studies in diabetic mice have revealed a superior
immunosuppressive activity for antigen-specific Tregs compared
to non-specific Tregs (140, 141). Furthermore, Tregs responding
to self-antigens have also been shown to suppress anti-tumor
immune responses (142, 143). Indications are that Tregs are likely
to play an important role in cancer immunology and elaborating
on the specificity of Tregs involved in antitumor responses could
be beneficial from a therapeutic perspective.
Immunotherapeutic Intervention in Cancer
Given the role of Tregs in immune evasion and tumor
progression, several studies have already suggested that
they are promising as therapeutic targets (31). Initially,
studies focused almost exclusively on the cancer cells as
targets for therapeutic interventions. However, cancer cells
frequently acquire therapeutic resistance because of inherent
genetic instability. Hence, working toward manipulation,
propagation, and therapeutic application of Tregs will provide
new and improved treatment options. The prognostic effect
of Tregs in different cancer types is important to take into
consideration when selecting a treatment strategy, and even
though Tregs appear as an obvious target for anti-tumor
treatment, manipulation of Treg mechanisms is not that simple
and more selective approaches for therapeutic strategies are
needed. This involves targeting of specific Treg subsets and
the inhibition or activation of Tregs depending on the type of
cancer (30). Furthermore, the composition of other immune
cells in the tumor microenvironment must also be taken
into account when assessing whether a patient will benefit
from immunotherapy. Recently an immune biomarker task
force elicited by the Society for Immunotherapy of Cancer
(SITC) sought to make recommendations of immune-related
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biomarkers that can predict the outcome of immunotherapy
in cancer patients (144). They focus on biomarkers in the
tumor microenvironment, gene expression at the tumor site,
tumor antigens, mutational load, peripheral biomarkers, and
host-related genetic biomarkers. Overall, this suggest that a
combination of personalized diagnostics is necessary in order
to assess immunocompentence of the individual. In terms of
this, an analysis of immune gene signatures should be feasible to
determine the potential for immunotherapy. Liu et al. performed
an extensive analysis on immunogenic signatures in triple-
negative breast cancer on two large-scale breast cancer genomic
datasets. They demonstrated that this type of breast cancer has
a strong tumor immunogenicity, which suggested that these
patients could benefit from immunotherapy (84).
Even though treatment by activation of the immune system
have proved to be successful it is not without side effects. One of
the biggest challenges of targeting Tregs and blocking immune
checkpoints is the development of severe system immune-related
side effects. Releasing the brake on the immune system can
lead to a systemic immune activation and might cause extensive
autoimmune reactions (31).
One branch of immunotherapy evolves around the idea
of activating the immune system targeting the regulatory
mechanisms that suppress an immune response against the
cancer. Especially, cancer therapy by inhibition of negative
immune regulation has proved very successful within recent
years in the form of immune checkpoint inhibitors and are
currently used in cancer immunotherapy. Discovery of the
two checkpoint molecules CTLA-4 and PD-1 that function as
brakes on the immune system has led to a new approach for
treating cancer patients. Ipilimumab and tremelimumab are two
well-characterized anti-CTLA-4 antibodies, the first approved
for treatment of malignant melanoma, colorectal cancer, and
renal cell carcinoma and the second being tested in clinical
trials on colorectal cancer and lung cancer patients (145–151).
Pembrolizumab is an anti-PD-1 drug approved for treatment of
multiple cancers including cervical cancer and melanoma (152–
155). Nivolumab is another anti-PD1 drug that in combination
with ipilimumab is used as first-line treatment of melanoma
being more effective than either agent alone (156). Furthermore,
nivolumab is shown to have a higher efficacy as compared
to chemotherapy in patients with melanoma, who progressed
after CTLA-4 treatment (157). These immunotherapies have
emphasized how manipulation of immune regulation is essential
for eradicating tumors.
Another strategy of breaking the tolerance to tumor tissue
is to inhibit the IDO pathway. Studies show that elimination
of IDO-positive immunosuppressive cells change the regulatory
microenvironment (158). Furthermore, it was found that 1-
methyl-tryptophan isomers capable of blocking IDO activity is
effective in reversing the suppression of T cells promoted by
DCs (159). Combined with other immune activating drugs, IDO
might also enhance the efficacy of immunotherapy by preventing
counter-regulation in response to immune activation (160).
Combining induction of IDO-specific immune responses with
anti-cancer immune therapy has the synergistic potential to both
eliminate cancer cells and immune suppressive cells expressing
IDO (158). Hence, clinical trials have been initiated to evaluate
the efficiency of IDO inhibitors and IDO-based vaccinations. A
combination of pembrolizumab and the selective IDO inhibitor
Epacadostat initially showed promising results increasing the
anti-tumor activity in patients with advanced solid tumors in
a phase I/II study (NCT02178722) (161). Unfortunately, no
benefit in survival was observed with the combined treatment
compared to pembrolizumab alone in the following phase III
clinical trial (NCT02752074) (162). A clinical phase I study have
shown that a vaccine with an epitope derived from IDO is well-
tolerated in patients with metastatic non-small cell lung cancer
(NCT01219348) (163). Currently, a clinical phase 2 study is
testing a combination therapy of the PD1 antibody Nivolumab
and a vaccine consisting of PD-L1 and IDO (NCT03047928).
A third way to enhance anti-tumor effects is to deplete Tregs
in the tumor microenvironment. Mouse studies have proven the
effectiveness of eliminating Tregs by administration of IFN-γ
and the use of IL-2 antibodies in combination with stimulation
of effector immune cells (140, 164). An ongoing clinical trial
is investigating a combination of pembrolizumab and low-
dose IL-2 in patients with advanced melanoma or renal cell
cancer (NCT03111901). Furthermore, a phase I/II study have
shown that CD4+CD25+ Treg depletion improves the graft-
vs.-tumor therapeutic effect of donor lymphocyte infusion in
patients suffering from hematopoietic malignancies and relapse
after standard allogeneic hematopoietic stem cell transplantation
(NCT00987987) (165).
Another branch of immunotherapy focuses on targeting
tumor antigens. Recognizing an increased activity for Tregs
that are antigen-specific gave the idea that Tregs could also be
exploited to target cancer cells. Expression of chimeric antigen
receptor (CAR) T cells to engineer T cells with antigen-specificity
toward cancer cells have already offered a promising strategy to
target diseases with extensive immune activation. This directs the
attention to a similar approach for Tregs with the possibility that
CAR Tregs could be used in Treg-mediated therapy reducing a
generalized immunosuppression (35). In terms of this, studies
have shown that it is possible to isolate CD4+CD25+ cells with
immunosuppressive function from peripheral blood and expand
them in vitro without loss of function, which represent a major
advance toward the therapeutic use of these cells in T cell-
mediated diseases (166). So far, engineered Tregs have been
shown to target the central nervous system reducing symptoms of
multiple sclerosis by suppression of inflammation and in colitis
patients CAR T cells could hinder development of colorectal
cancer (167, 168). This indicate that the use of engineered Tregs
is preferred in cancers with prominent inflammation and where
immune suppression will have a beneficial role in preventing
tumor progression. Moreover, a new study suggest a promising
role for CAR T cells in delivery of checkpoint inhibitors. Mouse
CAR T cells was modified to secrete PD-1 blocking single-chain
variable fragments and was shown to enhance the anti-tumor
function in mouse models of hematologic and solid tumor (169).
Hence, the targeted delivery of immune checkpoint inhibitors
or expression of other immunomodulatory molecules could
prevent systemic blockade, eventually improving treatment and
minimizing adverse side effects.
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THE ROLE OF TREGS IN REPRODUCTIVE
BIOLOGY
With the inheritance of half of the genes from the father, the fetus
is considered to be semi-allogenic in an immunological sense.
This results in the immunological paradox in which the maternal
immune system has to be able to tolerate the presence of the
foreign paternally derived antigens for a successful pregnancy
to take place. Initially, a shift from a Th1 pro-inflammatory
response toward an anti-inflammatory Th2 response has been
the central paradigm to explain the generation of fetal tolerance
(170). However, during normal pregnancy the decidua contains a
decreased CD4+/CD8+ ratio compared to the peripheral blood,
and decreased numbers of CCR6+ Th1, Th2, and Th17 cells,
while CCR6− Th1 cells and CD4+CD25hiFoxP3+/hi Tregs are
increased (171, 172). This reflects amuchmore complex scenario,
and are now explained as a balance between Th1, Th2, Th17, and
regulatory responses involving both innate and adaptive immune
cells (173, 174). Moreover, recently it has been proposed that the
immune system plays different roles in the different phases of
pregnancy; an inflammatory response seems necessary for the
implantation of the blastocyst, while there is an establishment
of a tolerogenic milieu for maintenance of the pregnancy, and
yet another shift toward inflammation at parturition (174, 175).
To constrain inflammation and avoid fetal rejection, several
mechanisms have developed in which increasing focus has
been giving to the role and function of the anti-inflammatory
properties of the regulatory Tregs (10, 173, 174, 176), which is
described in the next section.
Although maternal Teff cells are fully capable of recognizing
paternal antigens and become activated, this does not lead to
rejection of the fetus (177, 178). Tafuri et al. were also able to
show that paternally derived tumor cells were able to persist
during pregnancy independent of antibody response, but was
rejected after parturition (178). This indicates a pivotal role
for establishment of a temporal state of tolerance against the
paternal antigens during pregnancy, and thus an important
role for Tregs (178, 179). Several mechanisms have been
identified that protect the fetus from immune attack, including
attenuated expression of polymorphic Major Histocompatibility
Complex (MHC)/HLA proteins as well as expression of the
nearly monomorphic HLA class Ib molecules, release of anti-
inflammatory hormones, cytokines, and immunomodulatory
molecules by the placenta, and suppression of allo-reactive
responses (173). Fetal tolerance during pregnancy seems to be a
balance between clonal exhaustion (i.e., deletion or inactivation)
of allo-reactive T cells and immune regulation—a phenomenon
also seen in transplantation (180–182).
During the formation of the maternal-fetal interphase fetal
trophoblast cells will invade into the maternal decidua harboring
maternal immune cells to form the placenta. In parallel, the
tumor microenvironment can be seen as a pathological situation
with tumor cells with a distinct and possible non-self-phenotype
in close contact with immune cells (Figure 1). The placenta
is regarded as an immunological privileged site and is the
source of many immunomodulatory molecules, hormones and
cytokines that contributes to establishment of fetal tolerance
(183). Roughly speaking, there are two compartments in the
placenta in which maternal immune cells interact with the fetal
cells; the intervillous space and the decidua. The interactions
between the fetal trophoblast cells and the maternal T cells will
be different at the two places. The intervillous space is the space
between the anchoring villi, flooded with maternal blood that
allows exchange of nutrients. The syncytiotrophoblast cells here
lack the expression of all MHC/HLA molecules and should,
in theory, not be able to interact with the maternal T cells
(184). It has been suggested that the main role of the T cells
located here is to protect mother and fetus against infectious
pathogens (185). However, it should be noted that maternal
antigen presenting cells (APCs) are still able to induce an adaptive
immune response by presenting paternal antigens despite the
lack of MHC/HLA on the syncytiotrophoblast cells (186). In
contrast, invading extravillous trophoblasts (EVTs) present in the
decidua express a unique combination of HLA-C and the non-
classical HLA-E, -F, and -G molecules, enabling them to elicit
immunosuppression and induce tolerance. The expression of a
polymorphic paternally inherited HLA-C molecule on EVT has
the potential to induce alloreactivity toward the fetal-derived
cells. However, HLA-C is only expressed at a level of ∼10% of
HLA-A and -B, and HLA-C interacts both with T cells and NK
cells through KIRs (7, 184). In addition to the local immune
changes happening in the placenta during pregnancy, peripheral
tolerogenesis is also observed (187). It is not yet fully understood
whether the peripheral changes reflects the local changes or if
there is a separate systemic response to pregnancy, e.g., through
interaction with shed trophoblast debris or exosomes.
Many studies have shown the importance of Tregs for
pregnancy (10, 173, 174, 176). Tregs and FoxP3 mRNA have
been found in the endometrium throughout the menstrual
cycle, increasing in the follicular/estrus phase and thereby
the receptive phase, suggesting that the uterus is preparing
for pregnancy also involving immunomodulatory changes
(188, 189). Some studies might also indicate that the female
immune system is primed for pregnancy through contact with
antigens and immunomodulatory molecules present in the
seminal plasma during coitus (190). In mice, the CD4+ and
CD8+ Treg populations expand immediately after mating due
to activation by paternally derived antigens present in the
seminal fluid (186). Pregnant women have a higher level of
peripheral Tregs compared to non-pregnant women with Treg
numbers peaking during first and second trimester (191–194).
In parallel, higher levels of Tregs can also be observed in certain
cancer patients compared with healthy individuals as discussed
briefly previously. Moreover, it has been shown that women
with infertility problems and women experiencing recurrent
pregnancy loss (RPL) in first trimester have reduced number of
Tregs and FoxP3 mRNA, indicating an early role for Tregs in
the establishment of pregnancy (188, 195). The role of Tregs in
connection with the uterine (u)NK cells in the endometrium of
infertile women has been thoroughly described in a recent review
by Kofod et al. (196). Reduced numbers of Tregs, and increased
number of CD8+ T cells and Th17 cells, have also been associated
with pregnancy complications such as pre-eclampsia (PE) and
RPL (191, 192, 197). In mice, depletion of Tregs using anti-CD25
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monoclonal antibodies at the time of implantation resulted in
poor implantation and fetal reabsorption in allogeneic, but not
in syngeneic pregnancies. In contrast, no effect was observed
on either pregnancy outcome, blood pressure or urinary protein
levels, when Tregs were depleted later in pregnancy (182).
This confirms the proposed role for the Tregs in creating a
tolerogenic environment toward the paternal allo-antigens early
in implantation and pregnancy. It has been suggested that both
thymic and induced peripheral Tregs play important roles in
pregnancy. Mice studies have shown that pre-existing thymic
memory/activated Tregs specific for self-antigens are present very
early in pregnancy and thus play a role in implantation, whereas
depletion of peripheral Tregs leads to increased abortion later in
pregnancy (198). In human first trimester decidua, FoxP3hi Tregs
with a similar phenotype (CD45RO+HLA-DR+CTLA-4+) have
been identified (171). Analysis of Treg cells from term placenta
tissue also showed that these cells expressed GITR and had higher
expression of CD25, CTLA-4, and CD69 in comparison to their
peripheral counterparts, indicating an activated phenotype (194).
Lastly, recent studies have shown that pregnancy also leads to
the generation of both effector memory and central memory
CD4+ and CD8+ T cells that persist after pregnancy (199). The
development of memory Tregs after pregnancy and their possible
role for subsequent pregnancies remains to be elucidated.
Despite these observations, the exact role of the Tregs are still
poorly understood. Also, the activation and generation of Tregs
are dependent on recognition of antigen. Although mice studies
have shown that allo-reactive T cells are clonally deleted and
inactivated in a paternal antigen-specific manner, and like-wise,
that Tregs recognizing paternal antigens are generated during
pregnancy, the exact nature and origin of the antigen responsible
for generation of pregnancy-specific Tregs in natural settings
are sparse (180, 182). More studies are needed to understand,
whether the role of the Tregs is specifically to limit harmful pro-
inflammatory/Th1 and allo-reactive immune responses toward
the fetus, or whether the generation and function of the Tregs
are to limit general inflammatory responses in an environment
of tissue repair owed to the growing placenta (176).
Mechanisms of Treg-Mediated
Immunosuppression in Pregnancy
The mechanisms of fetal tolerance in pregnancy are many
and cannot exclusively be attributed to the generation of
fetal-specific Tregs. Tolerance include a balance between
clonal deletion and/or inactivation of allo-reactive effector
cells and immune suppression mediated by regulatory subsets
comprising both innate cells, such as tolerance-inducing DCs,
alternatively activated macrophages (M2) and the cytokine-
producing CD56brightCD16− decidual (d)NK cells, and adaptive
cells, including CD4+ and CD8+ Tregs as well as regulatory B
cells. All working together in an impressive network that secures
a successful pregnancy (200–202).
Cells of the endometrium and placenta release
numerous chemokines that play a role in orchestration of
immunomodulatory cells (203). In contrast to dNK cells, which
can be generated from CD34+ hematopoietic precursors present
in the human decidua (204, 205), Tregs seem to be recruited to
the uterus during estrus and in early pregnancy by chemokines
such as CCL1, CCL4, CCL17, and CCL22 (171, 189, 206).
In the pregnant mouse, the chemokine receptor CCR5
recognizing CCL4 is expressed by 70% of the CD4+CD25+
Tregs, and interaction of CCR8 with CCL1 has been shown
to enhance the immunosuppressive function of the Tregs by
inducing FoxP3 expression and IL-10, TGF-β and Granzyme B
production (189, 207).
The fetal trophoblast cells also express and release a number
of immunomodulatory molecules that contribute to the Treg
balance. Importantly, as seen in cancer and discussed above,
the attenuated expression of polymorphic HLA molecules in
addition to the expression of the non-classical HLA class Ib,
which show very limited polymorphism, are believed to protect
the fetal trophoblast cells from a direct cytotoxic response by
maternal Teff and NK cells (7, 208–210). Moreover, interactions
with HLA-G have been shown to induce the development of
immunosuppressive CD4+ T cells and suppress APCs (211,
212). A special CD8αα+ Treg cell that specifically identifies
Qa-1a (equivalent to the human MHC class Ib molecule HLA-
E), has been found to control activated CD4+ T cells in
mice (213). Furthermore, CD8αα+ cells have been shown to
infiltrate the ovaries during ovulation. Although the origin and
characterization of the nature of the CD8αα+ cell was unclear,
the CD8αα + cells seemed to originate from the thymus and
responded to the thymus-expressed chemokine (TECK), which is
important for T cell development. Importantly, it was found that
depletion of the CD8αα+ cells resulted in impaired fertility of the
female mice, suggesting a role in the establishment of pregnancy
(214). The role of CD8+ Tregs in pregnancy is unclear, however,
it would be interesting to study if any similar cell populations are
important for pregnancy in humans.
Negative regulators such as PD-L1 (215), the TNF family
members FasL (CD95L or Apoptosis Antigen (APO)-1L) and
tumor necrosis factor-related apoptosis inducing ligand (TRAIL;
CD235/APO-2L) (216–218) and IDO (219, 220) are also
expressed by the trophoblast cells. These molecules, as described
in previous sections, contribute to T cell homeostasis by inducing
apoptosis in allo-reactive Teff cells. Moreover, the trophoblast
cells also secrete IL-10 and TGF-β that contribute to Treg
recruitment and differentiation (221, 222), of which IL-10 also
has been shown to upregulate HLA-G, thus further contributing
to the Treg balance (223). As mentioned earlier, IL-10 and TGF-
β play an equally important role during cancer development.
However, in a cancer setting their pleiotrophic function imply
a more unclear effect on the Treg balance depending on
cancer type.
The function of Tregs during pregnancy mirror those
occurring in the tumor microenvironment, in which Tregs
regulate other immune cells present in the maternal-fetal
interphase (Figures 1, 3). Tregs limit the effect of allogen-specific
Teff cells by the expression of CD25, CTLA-4, and the PD-
L1 pathway and the secretion of IL-10 and TGF-β that induce
apoptosis and suppress cytotoxicity in recipient cells (171, 173,
176, 197). PD-L1 expression by Treg cells has been found
to inhibit proliferation of CD4+CD25− T cells and suppress
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expression of the pro-inflammatory cytokines IFN-γ and TNF-
α (224). PD-1 expression on T cells seem to be increased in
healthy pregnancy compared to non-pregnant women (225),
while reduced levels of PD-1 and PD-L1 have been suggested
to promote Th17 proliferation, thus causing the Treg/Th17
imbalance observed in PE (226). Consistent with this, mice
studies have shown that blocking of PD-L1 results in lower
numbers of Tregs and increased Teff and Th17 populations,
as well as increased fetal resorption and reduced litter size
(227, 228). Moreover, engagement with PD-L1 and secretion
of TGF-β promote the development of Tregs by increasing
FoxP3 expression, and reducing Teff cell development (227). The
immunosuppressive function of the PD1 pathway seems to work
by similar mechanisms in cancer and pregnancy, though with
opposite effect in terms of prognosis. Whereas, inhibition of the
pathway is desirable for activating the immune response against
cancer cells, activation and high PD-L1 expression is important
in terms of promoting a healthy pregnancy.
TheDCs are central for activation and differentiation of T cells
by presenting antigen and providing co-stimulatory signaling.
Formation of the placenta in early pregnancy is associated with
increased number of tolerogenic immature (i)DCs. These cells
have been shown to produce increased levels of IL-10 and induce
Treg formation during pregnancy (229–231). Further, Tregs
have been shown to induce the formation of anti-inflammatory
alternatively activated macrophages (M2), partly by IL-10 (232).
Moreover, Tregs secrete heme oxygenase-1 (HO-1) that keep
DCs in an immature state in which they secrete higher amounts
of IL-10 that further induce the formation of Tregs (233). In
turn, these cells secrete IDO and TGF-β and engage with the
CTLA-4 receptor on Tregs that together impairs allogen-specific
T cell activity and induce Treg formation, further affecting the
Tregs/Teff balance (234, 235).
Uterine and decidual NK cells play important regulatory
functions for the vascularization and formation of the placenta
in early pregnancy (236, 237). Like Tregs, a balance between
cytotoxic CD56dim and regulatory CD56bright NK cells seems
important for a successful pregnancy. Pregnancy complications
such as RPL and PE have also been linked to a reduced
CD56bright/CD56dim NK cell ratio (238, 239). Tregs might also be
important in regulation of the dNK cell phenotype. It has been
shown that Tregs reduce cytotoxicity of NK cells in an TGF-
β-dependent fashion and inhibit the release of IL-15 from DCs
that are important for the generation of dNK cells (240, 241).
Likewise, TGF-β secreted from decidual stroma cells has been
shown to change the peripheral CD56dim toward a decidual-
like CD56bright NK cell phenotype (242). It is likely that TGF-β
secreted from Tregs will have a similar effect on the NK cell
phenotype. On the contrary, NK cells are also able to contribute
to the Treg homeostasis by reducing Th17 cell responses through
the production of IFN-γ and inducing CD25+FoxP3+ Treg
development (235, 243).
Apart from the classical CD4+CD25+/hiFoxP3+ T cells
described above, other types of Tregs have also been associated
with pregnancy. As briefly addressed in previous sections recent
studies have identified an HLA-G-expressing CD4+ T cell
population with immunosuppressive functions. The HLA-G+
Tregs show an activated/memory phenotype (CD25+CD45RO+)
as the classical Treg cells, but lack the expression of FoxP3
(129). The CD4+HLA-G+ T cells are found at increased levels
in peripheral blood in pregnant women compared with non-
pregnant women. Additionally, one study reported that the
placenta was enriched in CD4+HLA-G+ T cells compared
to the peripheral compartment, and cases of PE have been
associated with reduced levels of the CD4+HLA-G+ T cell
subpopulation in both the decidua and in peripheral blood,
indicating an important role for pregnancy (129). As mentioned
earlier, HLA-G-expressing T cells are also observed in the tumor
microenvironment promoting a tolerogenic immune milieu, but
as with other immunological mechanisms having the same effect
during pregnancy and cancer development, a favorable effect is
actually opposite in the two settings. Immune suppression by
HLA-G is crucial in terms of a healthy pregnancy, but unwanted
in a cancer setting where it promotes tumor growth.
Taken together, it has become increasingly clear that Tregs
are an important player in the complex network of immune
cells that secure a healthy pregnancy. Regulatory T cells are
central regulators at the maternal-fetal interphase, as well as in
induction of peripheral tolerance during pregnancy. However,
it is also evident that the Tregs cannot stand alone. The
Treg cells regulate and are regulated by a variety of cells and
immune modulatory molecules. Their exact role and the precise
mechanism by which they exert their immune regulation needs
to be further elucidated.
Immunotherapeutic Intervention in
Pregnancy Complications
Clinical treatments based upon immunomodulating Treg
function in cases of infertility, pregnancy loss and pregnancy
complications have not yet been implemented in routine settings.
Regarding the use of Treg measurements as a diagnostic or
prognostic marker,Winger and Reed have reported an interesting
but small study of 54 pregnant women with a history of infertility
and/or pregnancy loss (195). In a new pregnancy, 23 of the
women experienced another pregnancy loss in the first trimester,
and 31 women were still pregnant after 12 weeks of gestation. The
percentage of CD4+CD25+FoxP3+ Tregs in peripheral blood
was significantly higher in the still pregnant >12 gestational
week compared with the pregnancy loss group at mean day 49.2
± 36.1 of the pregnancy. Based on the results from this pilot
study the authors propose that measurements of Tregs may serve
as a biomarker for the assessment of risk of pregnancy loss in
newly pregnant women. Clearly, larger studies are needed to
validate this.
In a ratmodel of pregnancy loss induced by the administration
of lipopolysaccharide (LPS) resulting in maternal inflammation
Renaud et al. showed that pregnancy loss could be prevented
by immunomodulation (244). This was either accomplished
by administration of IL-10 or by blockade of TNF-α by
a TNF-α inhibitor (Etanercept). As discussed previously,
studies especially in mice have shown the importance of the
presence of Tregs for a successful pregnancy. In one study by
Heitmann et al. a targeted depletion of Tregs was performed
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using a transgenic mouse model (245). It was observed that
embryo implantation in syngenic matings was defective after
Treg depletion. However, it was possible to restore embryo
implantation by the transfer of Tregs into the mating mice. It
can be speculated that administration or induction of pregnancy-
related Tregs resembling engineered T cells used in cancer
treatment could rescue some unsuccessful pregnancies caused
by abnormal Tregs function either by aberrant number of
cells or a functional defect. There might also be therapeutic
potential in blockage or the administration of specific cytokines
or HLA class Ib molecules locally in the female reproductive
tract. In theory, such immunomodulation might be able to
affect numbers or functionality of regulatory T cell subsets
beneficial for a successful pregnancy. However, this therapeutic
area clearly needs more studies primarily to clarify the basic
mechanisms upon which new therapeutic strategies may be
based on.
A reason as to why treatment based on immune modulation
is not extensively studied in terms of pregnancy complications
compared to the field of cancer immunotherapy, might be that
the focus on the cause of pregnancy complications such as
PE has been directed toward several different factors besides
immune regulation.
CONCLUSIONS AND PERSPECTIVES
Many similarities exist in the regulatory immune landscape of
the tumor microenvironment and at the feto-maternal interface
during pregnancy (Figure 1). While trophoblast cells possess
both maternal and paternal antigens, cancer is also a kind of
a chimera consisting of cells presenting both self and tumor-
associated antigens. Furthermore, it seems that the role of
Tregs in pregnancy and cancer, modulating the host response
directed toward foreign antigens in the placenta and the
tumor, respectively, may not be very different. Keeping this in
mind, the immunosuppressive role of Tregs in pregnancy is
a physiological process, while the inhibitory role of Tregs in
cancer is pathophysiological, which nevertheless also makes the
elaboration of immune modulating capacity in both cases even
more appealing. The apparent role of Tregs in early tolerance
induction is another issue also important in both cancer and
pregnancy. The early Treg response to embryo implantation is
similar to those in a cancer setting with Tregs being activated
within the first days of implantation and tumor emergence,
respectively (5, 198). Most essential in reproduction and cancer
immunology is the similar mechanisms of escape from host
immunosurveillance mediated by Tregs in combination with
other immune cells and immune factors. Therefore, investigating
mechanisms engaging Tregs and their regulation in apparently
distant fields like pregnancy and cancer have close connections
and could be highly beneficial (246). This would involve a better
mapping of cytokine networks and e.g., interactions with HLA
class Ib molecules in both situations.
Investigating the similarities in immunity through the
different trimesters in pregnancy and in advanced malignancies
has the potential to advance the knowledge of mechanisms
involved in Treg function and eventually help to overcome
the burden of long-term antigen exposure and immunologic
exhaustion. Treatment strategies can be aimed at aspects such
as invasion, angiogenesis, immune privilege, and malignant
proliferation (5). We can take advantage of the knowledge from
the two different fields of cancer and pregnancy complications
and potentially use it to facilitate the search for novel treatment
strategies in either of them.
Modification of the presence of Tregs and the function of these
cells have been studiedmore extensively in relation to cancer then
in the case of pregnancy complications, and treatment strategies
targeting immunosuppressive pathways are already established
for some cancers. However, more discoveries on Treg regulation
is essential for the exploitation of these cells both in the field
of cancer and reproductive immunology in order to improve
immunotherapy and to help prevent pregnancy complications.
Similar for both fields, future research in interactions of Tregs
with other cells, molecules responsible for recruitment of Tregs
into the maternal-fetal interface and tumor site, and intracellular
pathways of regulatory signaling in Treg cells, will be highly
valuable. Especially knowledge about the interactions of Tregs
with other immune cells is needed to provide safe treatment and
to reduce immune-related side effects (246).
AUTHOR CONTRIBUTIONS
NJ, GP, and TH participated in the design and draft of the
manuscript. NJ is the main author of sections dealing with
Tregs in cancer, while GP drafted sections regarding Tregs
in reproductive immunology. TH was responsible for overall
supervision and did the final proofreading of the draft. All
authors have read and accepted the final version of the
manuscript. The figures and the table included in the article
are made by the authors (Figure 1: TH and GP, Figures 2, 3:
GP, Table 1: NJ), and the figures and the table have not been
published before.
FUNDING
Support for this work was generously provided by The Region
Zealand Health Sciences Research Foundation and Zealand
University Hospital.
REFERENCES
1. Sakaguchi S. Naturally arising Foxp3-expressing CD25+
CD4+ regulatory T cells in immunological tolerance to self
and non-self. Nat Immunol. (2005) 6:345–52. doi: 10.1038/n
i1178
2. Waldmann H, Graca L, Cobbold S, Adams E, Tone M, Tone Y. Regulatory
T cells and organ transplantation. Semin Immunol. (2004) 16:119–26.
doi: 10.1016/j.smim.2003.12.007
3. Wahl SM, Vázquez N, Chen W. Regulatory T cells and transcription factors:
gatekeepers in allergic inflammation. Curr Opin Immunol. (2004) 16:768–74.
doi: 10.1016/j.coi.2004.09.006
Frontiers in Immunology | www.frontiersin.org 14 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
4. Munn DH, Mellor AL. The tumor-draining lymph node as
an immune-privileged site. Immunol Rev. (2006) 213:146–58.
doi: 10.1111/j.1600-065X.2006.00444.x
5. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy:
parallels in growth, invasion, and immune modulation and implications
for cancer therapeutic agents. Mayo Clin Proc. (2009) 84:985–1000.
doi: 10.1016/S0025-6196(11)60669-1
6. Hviid TVF. HLA-G in human reproduction: aspects of genetics, function
and pregnancy complications. Hum Reprod Update. (2006) 12:209–232.
doi: 10.1093/humupd/dmi048
7. Persson G, Melsted WN, Nilsson LL, Hviid TVF. HLA class Ib in
pregnancy and pregnancy-related disorders. Immunogenetics. (2017) 69:581–
95. doi: 10.1007/s00251-017-0988-4
8. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell
Res. (2017) 27:109–118. doi: 10.1038/cr.2016.151
9. Andersen MH. Immune regulation by self-recognition: novel possibilities
for anticancer immunotherapy. J Natl Cancer Inst. (2015) 107:djv154.
doi: 10.1093/jnci/djv154
10. Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance
in pregnancy: a new target for infertility treatment? Hum Reprod Update.
(2009) 15:517–35. doi: 10.1093/humupd/dmp004
11. Yu Y,MaX, Gong R, Zhu J,Wei L, Yao J. Recent advances in CD8+regulatory
T cell research. Oncol Lett. (2018) 15:8187–94. doi: 10.3892/ol.2018.8378
12. Zhang S, Wu M, Wang F. Immune regulation by CD8+ Treg cells: novel
possibilities for anticancer immunotherapy. Cell Mol Immunol. (2018)
15:805–7. doi: 10.1038/cmi.2018.170
13. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S,
et al. Persistence of naive CD45RA+ regulatoryTcells in adult life. Blood.
(2006) 107:2830–2838. doi: 10.1182/blood-2005-06-2403.Supported
14. Gershon RK, Cohen P, Hencin R, Liebhaber SA. Suppressor T cells. J
Immunol. (1972) 108:586–90.
15. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-
chains (CD25). Breakdown of a single mechanism of self-tolerance causes
various autoimmune diseases. J Immunol. (1995) 155:1151–64.
16. Thornton AM, Shevach EM. CD4 + CD25 + immunoregulatory T Cells
Suppress polyclonal T cell activation in vitro by inhibiting interleukin 2
production. J Exp Med. (1998) 188:287–96. doi: 10.1084/jem.188.2.287
17. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M,
et al. Immunologic self-tolerance maintained by CD25+CD4+naturally
anergic and suppressive T cells: Induction of autoimmune disease by
breaking their anergic/suppressive state. Int Immunol. (1998) 10:1969–80.
doi: 10.1093/intimm/10.12.1969
18. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH.
Identification and functional characterization of human Cd4 + Cd25 + T
cells with regulatory properties isolated from peripheral blood. J Exp Med.
(2001) 193:1285–94. doi: 10.1084/jem.193.11.1285
19. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, David A, et al.
Human CD4+CD25+ cells : a naturally occurring population of regulatory
T cells. Blood. (2013) 98:2736–44. doi: 10.1182/blood.V98.9.2736
20. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo
isolation and characterization of Cd4 + Cd25 + T cells with regulatory
properties from human blood. J Exp Med. (2001) 193:1303–10.
doi: 10.1084/jem.193.11.1303
21. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high
regulatory cells in human peripheral blood. J Immunol. (2001) 167:1245–53.
doi: 10.4049/jimmunol.167.3.1245
22. Hori S. Control of regulatory T cell development by the transcription factor
Foxp3. Science. (2003) 299:1057–61. doi: 10.1126/science.1079490
23. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for
Scurfin in CD4+CD25+T regulatory cells. J Immunol. (2003) 198:993–8.
doi: 10.1038/ni909
24. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development
and function of CD4+CD25+ regulatory T cells. Nat Immunol. (2003)
4:330–6. doi: 10.1038/ni904
25. Sun L, Yi S, O’Connell PJ. Foxp3 regulates human natural
CD4+CD25+ regulatory T-cell-mediated suppression of
xenogeneic response. Xenotransplantation. (2010) 17:121–30.
doi: 10.1111/j.1399-3089.2010.00571.x
26. Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, et al.
CD127 expression inversely correlates with FoxP3 and suppressive
function of human CD4+ T reg cells. J Exp Med. (2006) 203:1701–11.
doi: 10.1084/jem.20060772
27. Klein S, Kretz CC, Krammer PH, Kuhn A. CD127 low/and FoxP3
expression levels characterize different regulatory T-cell populations
in human peripheral blood. J Invest Dermatol. (2010) 130:492–9.
doi: 10.1038/jid.2009.313
28. Chien C-H, Chiang BL. Regulatory T cells induced by B cells: a
novel subpopulation of regulatory T cells. J Biomed Sci. (2017) 24:86.
doi: 10.1186/s12929-017-0391-3
29. Fontenot JD, Rasmussen JP,Williams LM, Dooley JL, Farr AG, Rudensky AY.
Regulatory T cell lineage specification by the forkhead transcription factor
Foxp3. Immunity. (2005) 22:329–41. doi: 10.1016/j.immuni.2005.01.016
30. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M,
et al. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism
of expansion in situ and clinical significance. Cancer Microenviron. (2013)
6:147–57. doi: 10.1007/s12307-012-0122-y
31. Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment
and cancer progression: role and therapeutic targeting. Vaccines. (2016) 4:28.
doi: 10.3390/vaccines4030028
32. Weiner HL. Induction and mechanism of action of transforming growth
factor-beta-secreting Th3 regulatory cells. Immunol Rev. (2001) 182:207–14.
doi: 10.1034/j.1600-065X.2001.1820117.x
33. Zeng H, Zhang R, Jin B, Chen L. Type 1 regulatory T cells: a new mechanism
of peripheral immune tolerance. Cell Mol Immunol. (2015) 12:566–71.
doi: 10.1038/cmi.2015.44
34. Jonuleit H, Schmitt E. The regulatory T cell family: distinct
subsets and their interrelations. J Immunol. (2003) 171:6323–7.
doi: 10.4049/jimmunol.171.12.6323
35. Hoeppli RE, MacDonald KG, Levings MK, Cook L. How antigen specificity
directs regulatory T-cell function: self, foreign and engineered specificity.
HLA. (2016) 88:3–13. doi: 10.1111/tan.12822
36. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-
Bucktrout S, et al. Neuropilin-1 distinguishes natural and inducible
regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. (2012)
209:1713–22. doi: 10.1084/jem.20120822
37. Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and
differences. Immunol Rev. (2014) 259:88–102. doi: 10.1111/imr.12160
38. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE,
Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor
family member, differentiates thymic-derived from peripherally
induced Foxp3 + T regulatory cells. J Immunol. (2010) 184:3433–1.
doi: 10.4049/jimmunol.0904028
39. Lin X, Chen M, Liu Y, Guo Z, He X, Brand D, et al. Advances in
distinguishing natural from induced Foxp3+ regulatory T cells. Int J.
(2013) 6:116–23. Retrieved from: http://www.ijcep.com/.
40. Dunussi-Joannopoulos K, LaBranche TP, Ryan MS, Medley QG, Keegan
SP, Collins M, et al. Enhanced GITR/GITRL interactions augment IL-27
expression and induce IL-10-producing Tr-1 like cells. Eur J Immunol. (2012)
42:1393–404. doi: 10.1002/eji.201142162
41. Mahmud SA, Manlove LS, Schmitz HM, Xing Y, Wang Y, Owen DL, et al.
Tumor necrosis factor receptor superfamily costimulation couples T cell
receptor signal strength to thymic regulatory T cell differentiation. Nat
Immunol. (2014) 15:473–81. doi: 10.1038/nature08728.An
42. Ronchetti S, Ricci E, Petrillo MG, Cari L, Migliorati G, Nocentini G, et al.
Glucocorticoid-induced tumour necrosis factor receptor-related protein:
a key marker of functional regulatory T cells. J Immunol Res. (2015)
2015:171520. doi: 10.1155/2015/171520
43. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223)
as a cancer immunotherapy target. Immunol Rev. (2017) 276:80–96.
doi: 10.1111/imr.12519
44. Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in
immunity and inflammation. Trends Mol Med. (2013) 19:355–67.
doi: 10.1016/j.molmed.2013.03.005
Frontiers in Immunology | www.frontiersin.org 15 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
45. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK, Johnson
JT, et al. Adenosine and prostaglandin e2 cooperate in the suppression of
immune responses mediated by adaptive regulatory T cells. J Biol Chem.
(2010) 285:27571–80. doi: 10.1074/jbc.M110.127100
46. Campbell DJ, Koch MA. Phenotypical and functional specialization
of FOXP3+ regulatory T cells. Nat Rev Immunol. (2011) 11:119–30.
doi: 10.1038/nri2916
47. Suto A, Nakajima H, Ikeda K, Kubo S, Nakayama T, Taniguchi M,
et al. CD4+CD25+T-cell development is regulated by at least 2 distinct
mechanisms. Blood. (2002) 99:555–60. doi: 10.1182/blood.V99.2.555
48. Pacholczyk R, Kraj P, Ignatowicz L. Peptide specificity of thymic
selection of CD4+CD25+ T cells. J Immunol. (2002) 168:613–20.
doi: 10.4049/jimmunol.168.2.613
49. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA,
et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an
agonist self-peptide. Nat Immunol. (2001) 2:301–6. doi: 10.1038/86302
50. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+
Immunoregulatory T cells is antigen nonspecific. J Immunol. (2000)
164:183–90. doi: 10.4049/jimmunol.164.1.183
51. Kosten IJ, Rustemeyer T. Generation, subsets and functions of inducible
regulatory T cells. Antiinflamm Antiallergy Agents Med Chem. (2015)
13:139–53. doi: 10.2174/1871523013666141126100019
52. Passerini L, Di Nunzio S, Gregori S, Gambineri E, Cecconi M, Seidel MG,
et al. Functional type 1 regulatory T cells develop regardless of FOXP3
mutations in patients with IPEX syndrome. Eur J Immunol. (2011) 41:1120–
31. doi: 10.1002/eji.201040909
53. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion
of peripheral CD4 CD25 naive T cells to CD4 CD25 regulatory T cells by
TGF-induction of transcription factor Foxp3. J Exp Med J Exp Med. (2003)
198:1875–86. doi: 10.1084/jem.20030152
54. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S,
Roncarolo MG. Growth and expansion of human T regulatory
type 1 cells are independent from TCR activation but require
exogenous cytokines. Eur J Immunol. (2002) 32:2237–45.
doi: 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2
55. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al.
A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents
colitis. Nature. (1997) 389:737–42. doi: 10.1038/39614
56. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt
R, Roncarolo MG. IFN-a and IL-10 induce the differentiation of
human Type 1 T regulatory cells. J Immunol. (2001) 166:5530–9.
doi: 10.4049/jimmunol.166.9.5530
57. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and
TGF-beta in the differentiation and effector function of T regulatory cells.
Int Arch Allergy Immunol. (2002) 129:263–76. doi: 10.1159/000067596
58. Chen Y, Kuchroo V, Inobe J, Hafler D, Weiner H. Regulatory T cell clones
induced by oral tolerance: suppression of autoimmune encephalomyelitis.
Science. (1994) 265:1237–40. doi: 10.1126/science.7520605
59. Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and TR1
and TH3 regulatory cells. Nat Immunol. (2001) 2:671–2. doi: 10.1038/90604
60. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler
DA. Induction of circulating myelin basic protein and proteolipid protein-
specific transforming growth factor-beta1-secreting Th3T cells by oral
administration of myelin in multiple sclerosis patients. J Clin Invest. (1996)
98:70–7. doi: 10.1172/JCI118779
61. Feger U, Tolosa E, Huang Y-H, Waschbisch A, Biedermann T, Melms A,
et al. HLA-G expression defines a novel regulatory T-cell subset present in
human peripheral blood and sites of inflammation. Blood. (2007) 110:568–
77. doi: 10.1182/blood-2006-11-057125
62. Pankratz S, Bittner S, Herrmann AM, Schuhmann MK, Ruck T, Meuth
SG, et al. Human CD4 + HLA-G + regulatory T cells are potent
suppressors of graft-versus-host disease in vivo. FASEB J. (2014) 28:3435–45.
doi: 10.1096/fj.14-251074
63. Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H. T cell
suppression by naturally occurring HLA-G-expressing regulatory CD4 +
T cells is IL-10-dependent and reversible. J Leukoc Biol. (2009) 86:273–81.
doi: 10.1189/jlb.1008649
64. Pankratz S, Ruck T, Meuth SG, Wiendl H. CD4+HLA-G+ regulatory T
cells: molecular signature and pathophysiological relevance. Hum Immunol.
(2016) 77:727–33. doi: 10.1016/j.humimm.2016.01.016
65. Fridman WH, Pagès F, Sauts-Fridman C, Galon J. The immune contexture
in human tumours: impact on clinical outcome. Nat Rev Cancer. (2012)
12:298–306. doi: 10.1038/nrc3245
66. Whiteside T. The role of regulatory T cells in cancer immunology.
ImmunoTargets Ther. (2015) 4:159–71. doi: 10.2147/ITT.S55415
67. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating
FoxP3+regulatory T cells in cancers: a systematic review and meta-analysis.
Sci Rep. (2015) 5:15179. doi: 10.1038/srep15179
68. Jacobs JFM, Nierkens S, Figdor CG, de Vries IJM, Adema GJ. Regulatory
T cells in melanoma: The final hurdle towards effective immunotherapy?
Lancet Oncol. (2012) 13:e32–42. doi: 10.1016/S1470-2045(11)70155-3
69. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters
immune privilege and predicts reduced survival. Nat Med. (2004) 10:942–9.
doi: 10.1038/nm1093
70. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF,
Korangy F. Increased Populations of Regulatory T cells in peripheral blood
of patients with hepatocellular carcinoma. Cancer Res. (2005) 65:2457–64.
doi: 10.1158/0008-5472.CAN-04-3232
71. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased
populations of regulatory T cells in peripheral blood and tumor-infiltrating
lymphocytes in patients with gastric and esophageal cancers.Clin Cancer Res.
(2003) 9:4404–8. Retrieved from: http://clincancerres.aacrjournals.org.
72. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced
frequencies and suppressive function of CD4+ CD25 hi regulatory T cells in
patients with chronic lymphocytic leukemia after therapy with fludarabine.
Blood. (2005) 106:2018–25. doi: 10.1182/blood-2005-02-0642.Supported
73. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are
associated with aggressive breast cancer phenotypes: a potential therapeutic
target.Mod Pathol. (2008) 21:1527–32. doi: 10.1038/modpathol.2008.160
74. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al.
CD4(+)CD25high regulatory T cells increase with tumor stage in patients
with gastric and esophageal cancers. Cancer Immunol Immunother. (2006)
55:1064–71. doi: 10.1007/s00262-005-0092-8
75. Liyanage UK, Moore TT, Joo H-GH-G, Tanaka Y, Herrmann V,
Doherty G, et al. Prevalence of regulatory T cells is increased in
peripheral blood and tumor microenvironment of patients with
pancreas or breast adenocarcinoma. J Immunol. (2002) 169:2756–61.
doi: 10.4049/jimmunol.169.5.2756
76. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic
analysis of immune infiltrates in high-grade serous ovarian cancer reveals
CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE. (2009)
4:e6412. doi: 10.1371/journal.pone.0006412
77. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon
S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are
selectively activated in lymphoid infiltrates surrounding primary breast
tumors and lead to an adverse clinical outcome. Cancer Res. (2009) 69:2000–
9. doi: 10.1158/0008-5472.CAN-08-2360
78. Demir L, Yigit S, Ellidokuz H, Erten C, Somali I, Kucukzeybek Y, et al.
Predictive and prognostic factors in locally advanced breast cancer: effect
of intratumoral FOXP3+ Tregs. Clin Exp Metastasis. (2013) 30:1047–62.
doi: 10.1007/s10585-013-9602-9
79. Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, et al. PD-
1+ immune cell infiltration inversely correlates with survival of operable
breast cancer patients. Cancer Immunol Immunother. (2014) 63:395–406.
doi: 10.1007/s00262-014-1519-x
80. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, et al.
Tumour-infiltrating FOXP3 + lymphocytes are associated with cytotoxic
immune responses and good clinical outcome in oestrogen receptor-negative
breast cancer. Br J Cancer. (2013) 108:155–62. doi: 10.1038/bjc.2012.524
81. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification
of regulatory T cells enables the identification of high-risk breast cancer
patients and those at risk of late relapse. J Clin Oncol. (2006) 24:5373–80.
doi: 10.1200/JCO.2006.05.9584
Frontiers in Immunology | www.frontiersin.org 16 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
82. Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, et al. Prognostic
significance of FOXP3+ tumor-infiltrating lymphocytes in breast
cancer depends on estrogen receptor and human epidermal growth
factor receptor-2 expression status and concurrent cytotoxic T-cell
infiltration. Breast Cancer Res. (2014) 16:432. doi: 10.1186/s13058-01
4-0432-8
83. Lee S, Cho EY, Park YH, Ahn JS, Im YH. Prognostic impact of FOXP3
expression in triple-negative breast cancer. Acta Oncol. (2013) 52:73–81.
doi: 10.3109/0284186X.2012.731520
84. Liu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic
portrait of triple-negative breast cancer. Transl Oncol. (2018) 11:311–29.
doi: 10.1016/j.tranon.2018.01.011
85. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al.
High frequency of tumor-infiltrating FOXP3 + regulatory T cells predicts
improved survival in mismatch repair-proficient colorectal cancer patients.
Int J Cancer. (2010) 2643:2635–43. doi: 10.1002/ijc.24989
86. Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, et al.
Tumor-derived chemokine CCL5 enhances TGF- -mediated killing of CD8+
T cells in colon cancer by T-regulatory cells. Cancer Res. (2012) 72:1092–102.
doi: 10.1158/0008-5472.CAN-11-2493
87. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+
regulatory T cells increases during the progression of pancreatic ductal
adenocarcinoma and its premalignant lesions. Clin Cancer Res. (2006)
12:5423–34. doi: 10.1158/1078-0432.CCR-06-0369
88. Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti
I, et al. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell
evaluation in predicting local recurrence in vertical growth phase cutaneous
melanoma. Oncol Rep. (2007) 18:1115–22. doi: 10.3892/or.18.5.1115
89. Ladányi A, Mohos A, Somlai B, Liszkay G, Gilde K, Fejos Z, et al.
FOXP3+cell density in primary tumor has no prognostic impact in patients
with cutaneous malignant melanoma. Pathol Oncol Res. (2010) 16:303–9.
doi: 10.1007/s12253-010-9254-x
90. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge
T, et al. FOXP3+ Regulatory T cells affect the development and
progression of hepatocarcinogenesis. Clin Cancer Res. (2007) 13:902–11.
doi: 10.1158/1078-0432.CCR-06-2363
91. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay NEH, et al.
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations
in head and neck cancers. Clin Cancer Res. (2006) 12:465–72.
doi: 10.1158/1078-0432.CCR-05-1886
92. Drennan S, Stafford ND, Greenman J, Green VL. Increased frequency and
suppressive activity of CD127 low/- Tregs in the peripheral circulation of
patients with head and neck squamous cell carcinoma are associated with
advanced stage and nodal involvement. Immunology. (2013) 140:335–43.
doi: 10.1111/imm.12144
93. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S.
Correlation of high numbers of intratumoral FOXP3+ regulatory T
cells with improved survival in germinal center-like diffuse large B-
cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma.
Haematologica. (2008) 93:193–200. doi: 10.3324/haematol.11702
94. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G,
et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells
are associated with improved overall survival in follicular lymphoma. Blood.
(2006) 108:2957–64. doi: 10.1182/blood-2006-04-018218
95. Álvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, et al.
Outcome in Hodgkin’s lymphoma can be predicted from the presence of
accompanying cytotoxic and regulatory T cells. Clin Cancer Res. (2005)
11:1467–73. doi: 10.1158/1078-0432.CCR-04-1869
96. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS,
et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T
cells in classical Hodgkin lymphoma. Hematol Oncol. (2009) 27:31–9.
doi: 10.1002/hon.878
97. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor
immunity by CTLA-4 blockade. Adv Sci. (2010) 271:1734–6.
doi: 10.1126/science.271.5256.1734
98. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV,
et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4
antibody blockade in previously vaccinated metastatic melanoma and
ovarian carcinoma patients. Proc Natl Acad Sci USA. (2003) 100:4712–7.
doi: 10.1073/pnas.0830997100
99. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M,
Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T
cell function. Science. (2008) 322:271–5. doi: 10.1126/science.11
60062
100. Onodera T, Jang MH, Guo Z, Yamasaki M, Hirata T, Bai Z, et al. Constitutive
expression of IDO by dendritic cells of mesenteric lymph nodes: functional
involvement of the CTLA-4/B7 and CCL22/CCR4 interactions. J Immunol.
(2009) 183:5608–14. doi: 10.4049/jimmunol.0804116
101. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine
2,3-dioxygenase expression in human cancers: clinical and
immunologic perspectives. Clin Cancer Res. (2011) 17:6985–91.
doi: 10.1158/1078-0432.CCR-11-1331
102. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer:
beyond IDO and tryptophan depletion. Cancer Res. (2012) 72:5435–40.
doi: 10.1158/0008-5472.CAN-12-0569
103. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of
lupus-like autoimmune diseases by disruption of the PD-1 gene encoding
an ITIM motif-carrying immunoreceptor. Immunity. (1999) 11:141–51.
doi: 10.1016/S1074-7613(00)80089-8
104. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al.
Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family
member leads to negative regulation of lymphocyte activation. J Exp Med.
(2000) 192:1027–34. doi: 10.1084/jem.192.7.1027
105. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread
of poorly immunogenic tumor cells by enhanced recruitment of effector T
cells. Int Immunol. (2005) 17:133–44. doi: 10.1093/intimm/dxh194
106. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation
of CD25+CD4+ regulatory T cells through GITR breaks immunological
self-tolerance. Nat Immunol. (2002) 3:135–42. doi: 10.1038/ni759
107. Stephens GL, Collins M, Shevach EM, Carreno BM, McHugh RS,
Young DA, et al. Engagement of Glucocorticoid-induced TNFR family-
related receptor on effector T cells by its ligand mediates resistance to
suppression by CD4+CD25+ T cells. J Immunol. (2014) 173:5008–20.
doi: 10.4049/jimmunol.173.8.5008
108. Hashiguchi S, Nishioka T, Takahashi T, Kanamaru F, Youngnak P.
T cells + regulatory CD4 + CD25 TNF receptor in both conventional
and costimulation via Glucocorticoid-induced Sakaguchi, Isao
Ishikawa and Miyuki Azuma. J Immunol Ref. (2004) 172:7306–7314.
doi: 10.4049/jimmunol.172.12.7306
109. Krausz LT, Fischer-Fodor E, Majorl ZZ, Fetica B. Gitr-expressing
regulatory T-cell subsets are increased in tumor-positive lymph
nodes from advanced breast cancer patients as compared to tumor-
negative lymph nodes. Int J Immunopathol Pharmacol. (2012) 25:59–66.
doi: 10.1177/039463201202500108
110. Silva JS, Tiezzi DG, Benevides L, Andrade JM, Marana HRC, Cardoso CRB.
Enrichment of regulatory T cells in invasive breast tumor correlates with
the upregulation of IL-17A expression and invasiveness of the tumor. Eur
J Immunol. (2013) 43:1518–28. doi: 10.1002/eji.201242951
111. Ephrem A, Epstein AL, Stephens GL, Thornton AM, Glass D, Shevach EM.
Modulation of Treg cells/T effector function by GITR signaling is context-
dependent. Eur J Immunol. (2013) 43:2421–9. doi: 10.1002/eji.201343451
112. Belkaid Y, Piccirillo CA, Mendez S. CD4+ CD25+ regulatory T cells control
Leishmania major persistence and immunity. Nature. (2002) 420:633–7.
doi: 10.1038/nature01199.1
113. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role
for interleukin 10 in the function of regulatory T cells that inhibit intestinal
inflammation. J Exp Med. (1999) 190:995–1004. doi: 10.1084/jem.190.7.995
114. Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, et al. IL-
10 controls ultraviolet-induced carcinogenesis in mice. J Immunol. (2007)
179:365–71. doi: 10.4049/jimmunol.179.1.365
115. Landskron G, la Fuente MD, Thuwajit P, Thuwajit C, HermosoMA. Chronic
Inflammation and Cytokines in the Tumor Microenvironment. J Immunol
Res. (2014) 2014:149185. doi: 10.1155/2014/149185
116. Surh CD, Bayer AL, de la Barrera A, Lee JY, Malek TR. A function for IL-7R
for CD4+CD25+Foxp3+ T regulatory cells. J Immunol. (2014) 181:225–34.
doi: 10.4049/jimmunol.181.1.225
Frontiers in Immunology | www.frontiersin.org 17 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
117. Hoeppli RE, Wu D, Cook L, Levings MK. The environment of regulatory
T cell biology: cytokines, metabolites, and the microbiome. Front Immunol.
(2015) 6:61. doi: 10.3389/fimmu.2015.00061
118. Carosella ED, Rouas-Freiss N, Le Roux DT, Moreau P, LeMaoult J. HLA-G.
An Immune Checkpoint Molecule. Adv Immunol. 1st ed. Paris: Elsevier Inc.
(2015) 127:33–144. doi: 10.1016/bs.ai.2015.04.001
119. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit
VTHBM, et al. Prognostic value of tumor–stroma ratio combined with the
immune status of tumors in invasive breast carcinoma. Breast Cancer Res
Treat. (2017) 168:601–12. doi: 10.1007/s10549-017-4617-6
120. de Kruijf EM, Sajet A, van Nes JGH, Natanov R, Putter H, Smit VTHBM,
et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors
is of prognostic value for clinical outcome of early breast cancer patients. J
Immunol. (2010) 185:7452–59. doi: 10.4049/jimmunol.1002629
121. Ramos CS, Gonçalves AS,Marinho LC, Gomes AvelinoMA, Saddi VA, Lopes
AC, et al. Analysis of HLA-G gene polymorphism and protein expression
in invasive breast ductal carcinoma. Hum Immunol. (2014) 75:667–72.
doi: 10.1016/j.humimm.2014.04.005
122. Ueshima C, Kataoka TR, Hirata M, Furuhata A, Suzuki E, Toi M, et al.
The killer cell Ig-like receptor 2DL4 expression in human mast cells and
its potential role in breast cancer invasion. Cancer Immunol Res. (2015)
3:871–80. doi: 10.1158/2326-6066.CIR-14-0199
123. da Silva GBRF, Silva TGA, Duarte RA, Neto NL, Carrara HHA, Donadi EA,
et al. Expression of the classical and nonclassical HLA molecules in breast
cancer. Int J Breast Cancer. (2013) 2013:250435. doi: 10.1155/2013/250435
124. Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, et al. Human leukocyte
antigen-G is closely associated with tumor immune escape in gastric cancer
by increasing local regulatory T cells. Cancer Sci. (2011) 102:1272–80.
doi: 10.1111/j.1349-7006.2011.01951.x
125. Adrián Cabestré F, Moreau P, Riteau B, Ibrahim EC, Le Danff
C, Dausset J, et al. HLA-G expression in human melanoma cells:
Protection from NK cytolysis. J Reprod Immunol. (1999) 43:183–93.
doi: 10.1016/S0165-0378(99)00037-6
126. MelstedWN, Johansen LL, Lock-Andersen J, Behrendt N, Eriksen JO, Bzorek
M, et al. HLA class Ia and Ib molecules and FOXP3+ TILs in relation to the
prognosis of malignant melanoma patients.Clin Immunol. (2017) 183:191–7.
doi: 10.1016/j.clim.2017.09.004
127. Melsted WN, Matzen SH, Andersen MH, Hviid TVF. The choriocarcinoma
cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-
inflammatory cytokines through HLA-G. Cell Immunol. (2017) 324:14–23.
doi: 10.1016/j.cellimm.2017.11.008
128. Wang C, Chen J, ZhangQ, LiW, Zhang S, Xu Y, et al. Elimination of CD4 low
HLA-G+T cells overcomes castration- resistance in prostate cancer therapy.
(2018) Cell Res. (2018) 28:1103–17. doi: 10.1038/s41422-018-0089-4
129. Hsu P, Santner-Nanan B, Joung S, Peek MJ, Nanan R. Expansion of
CD4+HLA-G+T cell in human pregnancy is impaired in pre-eclampsia.Am
J Reprod Immunol. (2014) 71:217–28. doi: 10.1111/aji.12195
130. Darrasse-Jèze G, Podsypanina K. How numbers, nature, and immune
status of Foxp3+regulatory T-cells shape the early immunological events in
tumor development. Front Immunol. (2013) 4:292. doi: 10.3389/fimmu.2013.
00292
131. Darrasse-Jèze G, Bergot A, Durgeau A, Billiard F, Salomon BL, Cohen JL,
et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that
create a dominant tolerogenic environment for tumors in mice. J Clin Invest.
(2009) 119:2648–62. doi: 10.1172/JCI36628
132. Bhatnagar RM, Zabriskie JB, Rausen AR. Cellular immune responses to
methylcholanthrene-induced fibrosarcoma in BALB/c mice. J Exp Med.
(1975) 142:839–55. doi: 10.1084/jem.142.4.839
133. Savage PA, Leventhal DS, Malchow S. Shaping the repertoire of tumor-
infiltrating effector and regulatory T cells. Immunol Rev. (2014) 259:245–58.
doi: 10.1111/imr.12166
134. Lu Y-C, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin
Immunol. (2016) 28:22–7. doi: 10.1016/j.smim.2015.11.002
135. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, et al.
Tumor-specific human CD4+regulatory T cells and their ligands:
implications for immunotherapy. Immunity. (2004) 20:107–18.
doi: 10.1016/S1074-7613(03)00359-5
136. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of
a New ARTC1 peptide ligand uniquely expressed in tumor cells by
antigen-specific CD4+ regulatory T cells. J Immunol. (2005) 174:2661–70.
doi: 10.4049/jimmunol.174.5.2661
137. Vence L, Palucka AK, Fay JW, Ito T, Liu Y-J, Banchereau J, et al.
Circulating tumor antigen-specific regulatory T cells in patients with
metastatic melanoma. Proc Natl Acad Sci USA. (2007) 104:20884–9.
doi: 10.1073/pnas.0710557105
138. Bonertz A, Weitz J, Pietsch DK, Rahbari NN, Schlude C, Ge Y, et al.
Antigen-specific Tregs control T cell responses against a limited repertoire of
tumor antigens in patients with colorectal carcinoma. J Clin Investig. (2009)
119:3311–21. doi: 10.1172/JCI39608.tumor
139. Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, et al.
Suppression of tumour-specific CD4 + T cells by regulatory T cells
is associated with progression of human colorectal cancer. Gut. (2012)
61:1163–71. doi: 10.1136/gutjnl-2011-300970
140. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing
regulatory T cell control of autoimmune responses in nonobese diabetic
mice. Nat Immunol. (2006) 7:83–92. doi: 10.1038/ni1289
141. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25 + CD4
+ T cells, expanded with dendritic cells presenting a single autoantigenic
peptide, suppress autoimmune diabetes. J Exp Med. (2004) 199:1467–77.
doi: 10.1084/jem.20040180
142. Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, et al. CD4+
CD25+ T cells responding to serologically defined autoantigens suppress
antitumor immune responses. Proc Natl Acad Sci USA. (2003) 100:10902–6.
doi: 10.1073/pnas.1834479100
143. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, et al.
Aire-dependent thymic development of tumor-associated regulatory T cells.
Science. (2013) 339:1219–24. doi: 10.1126/science.1233913
144. Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al.
Identifying baseline immune-related biomarkers to predict clinical
outcome of immunotherapy. J Immunother Cancer. (2017) 5:44.
doi: 10.1186/s40425-017-0243-4
145. Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma:
serious side effects and a hefty price tag may limit its use. P T. (2012)
37:503–30. Retrieved from: https://www.ptcommunity.com/.
146. OvermanMJ, Lonardi S,WongKYM, LenzHJ, Gelsomino F, AgliettaM, et al.
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch
repair–deficient/microsatellite instability–high metastatic colorectal cancer.
J Clin Oncol. (2018) 36:773–9. doi: 10.1200/JCO.2017.76.9901
147. Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok
JD, Schmidt H, et al. Prolonged survival in stage III melanoma
with ipilimumab adjuvant therapy. N Engl J Med. (2016) 375:1845–55.
doi: 10.1056/NEJMoa1611299
148. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improved survival with ipilimumab in patients with metastatic melanoma.N
Engl J Med. (2010) 363:711–23. doi: 10.1056/NEJMoa1003466
149. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar
B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib
in advanced renal-cell carcinoma. N Engl J Med. (2018) 378:1277–90.
doi: 10.1056/NEJMoa1712126
150. Fumet J-D, Isambert N, Hervieu A, Zanetta S, Guion J-F, Hennequin A,
et al. Phase Ib/II trial evaluating the safety, tolerability and immunological
activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-
CTLA-4) combined with FOLFOX in patients with metastatic colorectal
cancer. ESMO Open. (2018) 3:e000375. doi: 10.1136/esmoopen-2018-0
00375
151. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta
A, et al. Safety and antitumour activity of durvalumab plus tremelimumab
in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol.
(2016) 17:299–308. doi: 10.1016/S1470-2045(15)00544-6
152. Martínez P, del Campo JM. Pembrolizumab in recurrent advanced
cervical squamous carcinoma. Immunotherapy. (2017) 9:467–70.
doi: 10.2217/imt-2016-0119
153. Frenel J-S, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C,
et al. Safety and efficacy of pembrolizumab in advanced, programmed death
Frontiers in Immunology | www.frontiersin.org 18 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028
trial. J Clin Oncol. (2017) 35:4035–41. doi: 10.1200/JCO.2017.74.5471
154. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
(2015) 372:2521–32. doi: 10.1056/NEJMoa1503093
155. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L,
et al. Pembrolizumab versus ipilimumab for advanced melanoma:
final overall survival results of a multicentre, randomised, open-
label phase 3 study (KEYNOTE-006). Lancet. (2017) 390:1853–62.
doi: 10.1016/S0140-6736(17)31601-X
156. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD,
et al. Combined nivolumab and ipilimumab or monotherapy in untreated
melanoma. N Engl J Med. (2015) 373:23–34. doi: 10.1056/NEJMoa1504030
157. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who
progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised,
controlled, open-label, phase 3 trial. Lancet Oncol. (2015) 16:375–84.
doi: 10.1016/S1470-2045(15)70076-8
158. AndersenMH. The specific targeting of immune regulation: T-cell responses
against Indoleamine 2,3-dioxygenase. Cancer Immunol Immunother. (2012)
61:1289–97. doi: 10.1007/s00262-012-1234-4
159. Hou DY, Muller AJ, SharmaMD, DuHadaway J, Banerjee T, JohnsonM, et al.
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers
of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res.
(2007) 67:792–801. doi: 10.1158/0008-5472.CAN-06-2925
160. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance
and counter-regulation. Curr Opin Immunol. (2006) 18:220–5.
doi: 10.1016/j.coi.2006.01.002
161. Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski
AJ, et al. Epacadostat plus pembrolizumab in patients with advanced
solid tumors: phase I results from a multicenter, open-label phase
I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol. (2018) 36:3223–30.
doi: 10.1200/JCO.2018.78.9602
162. Long GV, Dummer R, Hamid O, Gajewski T, Caglevic C, Dalle S, et al.
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in
patients (pts) with unresectable or metastatic melanoma: results of the
phase 3 ECHO-301/KEYNOTE-252 study. J Clin Oncol. (2018) 36:108.
doi: 10.1200/JCO.2018.36.15_suppl.108
163. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK,
Bjoern J, et al. Long-lasting disease stabilization in the absence of toxicity
in metastatic lung cancer patients vaccinated with an epitope derived
from indoleamine 2,3 dioxygenase. Clin Cancer Res. (2014) 20:221–32.
doi: 10.1158/1078-0432.CCR-13-1560
164. Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato
N, et al. Interleukin-2-dependent mechanisms of tolerance and immunity
in vivo. J Immunol. (2006) 176:5255–66. doi: 10.4049/jimmunol.176.9.5255
165. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cherai
M, et al. CD4+CD25+ regulatory T cell depletion improves the
graft-versus-tumor effect of donor lymphocytes after allogeneic
hematopoietic stem cell transplantation. Sci Transl Med. (2010) 2:41ra52.
doi: 10.1126/scitranslmed.3001302
166. Levings MK, Sangregorio R, Roncarolo M-G. Human CD25+CD4+ T
regulatory cells suppress naive and memory T cell proliferation and can be
expanded in vitro without loss of function. J Exp Med. (2001) 193:1295–302.
doi: 10.1084/jem.193.11.1295
167. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine
colitis and its associated cancer by carcinoembryonic antigen-specific
regulatory T cells.Mol Ther. (2014) 22:1018–28. doi: 10.1038/mt.2014.41
168. Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, et al.
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress
EAE upon intranasal delivery. J Neuroinflammation. (2012) 9:576.
doi: 10.1186/1742-2094-9-112
169. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes
DJ, et al. Targeted delivery of a PD-1-blocking scFV by CAR-T cells
enhances anti-tumor efficacy in vivo. Nat Biotechnol. (2018) 36:847–58.
doi: 10.1038/nbt.4195
170. Wegmann TG, Lin H, Mosmann TR. Bidirectional cytokine interactions in
the maternal-fetal relationshi : is successful pregnancy a Th 2 phenomenon?
Immunol Today. (1993) 14:353–6. doi: 10.1016/0167-5699(93)
90235-D
171. Mjösberg J, Berg G, Jenmalm MC, Ernerudh J. FOXP3+ regulatory
T cells and T Helper 1, T Helper 2, and T Helper 17 cells in
human early pregnancy Decidua1. Biol Reprod. (2010) 82:698–705.
doi: 10.1095/biolreprod.109.081208
172. Erkers T, Stikvoort A, Uhlin M. Lymphocytes in placental tissues: immune
regulation and translational possibilities for immunotherapy. Stem Cells Int.
(2017) 2017:1–17. doi: 10.1155/2017/5738371
173. Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo
implantation and the immune response to pregnancy. J Clin Invest. (2018)
128:4224–35. doi: 10.1172/JCI122182
174. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-
cell paradigm in pregnancy. Am J Reprod Immunol. (2010) 63:601–10.
doi: 10.1111/j.1600-0897.2010.00852.x
175. Chavan AR, Griffith OW, Wagner GP. The inflammation paradox in the
evolution of mammalian pregnancy: turning a foe into a friend. Curr Opin
Genet Dev. (2017) 47:24–32. doi: 10.1016/j.gde.2017.08.004
176. Powell RM. Novel T Cell Function and Specificity at the Human Maternal-
Fetal Interface. (2018) Available online at: http://etheses.bham.ac.uk/8334/
(accessed September 4, 2018).
177. Tilburgs T, Scherjon SA, van der Mast BJ, Haasnoot GW, Versteeg-
V.D.Voort-Maarschalk M, Roelen DL, et al. Fetal-maternal HLA-C
mismatch is associated with decidual T cell activation and induction
of functional T regulatory cells. J Reprod Immunol. (2009) 82:147–56.
doi: 10.1016/j.jri.2009.05.003
178. Tafuri A, Alferink J, Möller P, Hämmerling GJ, Arnold B. T cell awareness
of paternal alloantigens during pregnancy. Science. (1995) 270:630–3.
doi: 10.1126/science.270.5236.630
179. Gleicher N, Kushnir VA, Barad DH. Redirecting reproductive immunology
research toward pregnancy as a period of temporary immune tolerance. J
Assist Reprod Genet. (2017) 34:425–30. doi: 10.1007/s10815-017-0874-x
180. Jiang SP, Vacchio MS. Multiple mechanisms of peripheral T cell tolerance to
the fetal “allograft”. J Immunol. (1998) 160:3086–90.
181. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat
Rev Immunol. (2003) 3:223–32. doi: 10.1038/nri1029
182. Shima T, Sasaki Y, Itoh M, Nakashima A, Ishii N, Sugamura K, et al.
Regulatory T cells are necessary for implantation and maintenance of early
pregnancy but not late pregnancy in allogeneic mice. J Reprod Immunol.
(2010) 85:121–9. doi: 10.1016/j.jri.2010.02.006
183. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced
inflammatory and regulatory cytokines in pregnancy and the
etiology of preeclampsia. Semin Immunopathol. (2007) 29:151–62.
doi: 10.1007/s00281-007-0071-6
184. Apps R, Murphy SP, Fernando R, Gardner L, Ahad T, Moffett A. Human
leucocyte antigen (HLA) expression of primary trophoblast cells and
placental cell lines, determined using single antigen beads to characterize
allotype specificities of anti-HLA antibodies. Immunology. (2009) 127:26–39.
doi: 10.1111/j.1365-2567.2008.03019.x
185. Solders M, Gorchs L, Erkers T, Lundell AC, Nava S, Gidlöf S, et al.
MAIT cells accumulate in placental intervillous space and display a highly
cytotoxic phenotype upon bacterial stimulation. Sci Rep. (2017) 7:6123.
doi: 10.1038/s41598-017-06430-6
186. Moldenhauer LM, Diener KR, Thring DM, Brown MP, Hayball JD,
Robertson SA. Cross-presentation of male seminal fluid antigens elicits T cell
activation to initiate the female immune response to pregnancy. J Immunol.
(2009) 182:8080–93. doi: 10.4049/jimmunol.0804018
187. Jin LP, Chen QY, Zhang T, Guo PF, Li DJ. The CD4+CD25bright regulatory
T cells and CTLA-4 expression in peripheral and decidual lymphocytes are
down-regulated in human miscarriage. Clin Immunol. (2009) 133:402–10.
doi: 10.1016/J.CLIM.2009.08.009
188. Jasper MJ, Tremellen KP, Robertson SA. Primary unexplained infertility is
associated with reduced expression of the T-regulatory cell transcription
factor Foxp3 in endometrial tissue. Mol Hum Reprod. (2006) 12:301–8.
doi: 10.1093/molehr/gal032
189. Kallikourdis M, Betz AG. Periodic accumulation of regulatory T cells in the
uterus: Preparation for the implantation of a semi-allogeneic fetus? PLoS
ONE. (2007) 2:e382. doi: 10.1371/journal.pone.0000382
Frontiers in Immunology | www.frontiersin.org 19 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
190. Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD. Activating
T regulatory cells for tolerance in early pregnancy-the contribution of
seminal fluid. J Reprod Immunol. (2009) 83:109–16. doi: 10.1016/j.jri.2009.
08.003
191. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, Shima T,
et al. Proportion of peripheral blood and decidual CD4(+) CD25(bright)
regulatory T cells in pre-eclampsia. Clin Exp Immunol. (2007) 149:139–45.
doi: 10.1111/j.1365-2249.2007.03397.x
192. Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St.
Groth B, et al. Systemic increase in the ratio between Foxp3+ and IL-17-
producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J
Immunol. (2009) 183:7023–30. doi: 10.1111/j.1096-3642.1945.tb00854.x
193. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal
human pregnancy is associated with an elevation in the immune suppressive
CD25 + CD4 + regulatory T-cell subset. Immunology. (2004) 112:38–43.
doi: 10.1111/j.1365-2567.2004.01869.x
194. Heikkinen J, Möttönen M, Alanen A, Lassila O. Phenotypic characterization
of regulatory T cells in the human decidua. Clin Exp Immunol. (2004)
136:373–8. doi: 10.1111/j.1365-2249.2004.02441.x
195. Winger EE, Reed JL. Low Circulating CD4+ CD25+ Foxp3+ T
regulatory cell levels predict miscarriage risk in newly pregnant women
with a history of failure. Am J Reprod Immunol. (2011) 66:320–8.
doi: 10.1111/j.1600-0897.2011.00992.x
196. Kofod L, Lindhard A, Hviid TVF. Implications of uterine NK cells and
regulatory T cells in the endometrium of infertile women. Hum Immunol.
(2018) 79:693–701. doi: 10.1016/j.humimm.2018.07.003
197. Abdolmohammadi Vahid S, Ghaebi M, Ahmadi M, Nouri M, Danaei
S, Aghebati-Maleki L, et al. Altered T-cell subpopulations in recurrent
pregnancy loss patients with cellular immune abnormalities. J Cell Physiol.
(2018) 234:4924–33. doi: 10.1002/jcp.27290
198. Chen T, Darrasse-Jeze G, Bergot AS, Courau T, Churlaud G, Valdivia K, et al.
Self-specific memory regulatory t cells protect embryos at implantation in
mice. J Immunol. (2013) 191:2273–81. doi: 10.4049/jimmunol.1202413
199. Kieffer TEC, Faas MM, Scherjon SA, Prins JR. Pregnancy persistently
affects memory T cell populations. J Reprod Immunol. (2017) 119:1–8.
doi: 10.1016/j.jri.2016.11.004
200. Liu S, Diao L, Huang C, Li Y, Zeng Y, Kwak-Kim JYH. The role of decidual
immune cells on human pregnancy. J Reprod Immunol. (2017) 124:44–53.
doi: 10.1016/j.jri.2017.10.045
201. Munoz-Suano A, Hamilton AB, Betz AG. Gimme shelter: the
immune system during pregnancy. Immunol Rev. (2011) 241:20–38.
doi: 10.1111/j.1600-065X.2011.01002.x
202. Muzzio D, Zenclussen AC, Jensen F. The role of B cells in pregnancy:
the good and the bad. Am J Reprod Immunol. (2013) 69:408–12.
doi: 10.1111/aji.12079
203. Ramhorst R, Grasso E, Paparini D, Hauk V, Gallino L, Calo G, et al. Decoding
the chemokine network that links leukocytes with decidual cells and the
trophoblast during early implantation. Cell Adh Migr. (2016) 10:197–207.
doi: 10.1080/19336918.2015.1135285
204. Chiossone L, Vacca P, Orecchia P, Croxatto D, Damonte P, Astigiano
S, et al. In vivo generation of decidual natural killer cells from
resident hematopoietic progenitors. Haematologica. (2014) 99:448–57.
doi: 10.3324/haematol.2013.091421
205. Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E, et al.
CD34 + hematopoietic precursors are present in human decidua and
differentiate into natural killer cells upon interaction with stromal cells.
Proc Natl Acad Sci USA. (2010) 108:2402–7. doi: 10.1073/pnas.10162
57108
206. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia
F, et al. Unique chemotactic response profile and specific expression of
chemokine receptors Ccr4 and Ccr8 by Cd4 + Cd25 + regulatory T cells.
J Exp Med. (2001) 194:847–54. doi: 10.1084/jem.194.6.847
207. Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J,
et al. CCR8 + FOXp3 + T reg cells as master drivers of immune regulation.
Proc Natl Acad Sci USA. (2017) 114:6086–91. doi: 10.1073/pnas.16212
80114
208. Hviid TVF, Hylenius S, Lindhard A, Christiansen OB. Association
between human leukocyte antigen-G genotype and success of in vitro
fertilization and pregnancy outcome. Tissue Antigens. (2004) 64:66–9.
doi: 10.1111/j.1399-0039.2004.00239.x
209. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt
H, et al. Protein expression and peptide binding suggest unique
and interacting functional roles for HLA-E, F, and G in maternal-
placental immune recognition. J Immunol. (2003) 171:1376–84.
doi: 10.4049/jimmunol.171.3.1376
210. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, et al. Soluble
HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells
and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol.
(2003) 33:125–34. doi: 10.1002/immu.200390015
211. Horuzsko A, Lenfant F, Munn DH, Mellor AL. Maturation of antigen-
presenting cells is compromised in HLA-G transgenic mice. Int Immunol.
(2001) 13:385–94. doi: 10.1093/intimm/13.3.385
212. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-
G1-expressing antigen-presenting cells induce immunosuppressive
CD4+ T cells. Proc Natl Acad Sci USA. (2004) 101:7064–9.
doi: 10.1073/pnas.0401922101
213. Tang X, Maricic I, Purohit N, Bakamjian B, Reed-Loisel LM, Beeston
T, et al. Regulation of immunity by a novel population of Qa-1-
restricted CD8 +TCR + T cells. J Immunol. (2006) 177:7645–55.
doi: 10.4049/jimmunol.177.11.7645
214. Zhou C, Wu J, Borillo J, Torres L, McMahon J, Lou YH. Potential roles
of a special CD8 + cell population and CC chemokine thymus-expressed
chemokine in ovulation related inflammation. J Immunol. (2009) 182:596–
603. doi: 10.4049/jimmunol.182.1.596
215. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman
GJ, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during
normal and autoimmune responses. Eur J Immunol. (2003) 33:2706–16.
doi: 10.1002/eji.200324228
216. Mor G, Gutierrez LS, Eliza M, Kahyaoglu F, Arici A. Fas-Fas
ligand system-induced apoptosis in human placenta and gestational
trophoblastic disease. Am J Reprod Immunol. (1998) 40:89–94.
doi: 10.1111/j.1600-0897.1998.tb00396.x
217. Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L. Exosomes
secreted by human placenta carry functional Fas Ligand and TRAIL
molecules and convey apoptosis in activated immune cells, suggesting
exosome-mediated immune privilege of the fetus. J Immunol. (2013)
191:5515–23. doi: 10.4049/jimmunol.1301885
218. Vacchio MS, Hodes RJ. Fetal expression of Fas Ligand is necessary
and sufficient for induction of CD8T cell tolerance to the fetal
antigen H-Y during pregnancy. J Immunol. (2005) 174:4657–61.
doi: 10.4049/jimmunol.174.8.4657
219. Hönig A, Rieger L, Kapp M, Sütterlin M, Dietl J, Kämmerer U. Indoleamine
2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast
supports role of the enzyme for materno-fetal tolerance. J Reprod Immunol.
(2004) 61:79–86. doi: 10.1016/J.JRI.2003.11.002
220. Zong S, Li C, Luo C, Zhao X, Liu C, Wang K, et al. Dysregulated expression
of IDO may cause unexplained recurrent spontaneous abortion through
suppression of trophoblast cell proliferation and migration. Sci Rep. (2016)
6:19916. doi: 10.1038/srep19916
221. Ramhorst R, Fraccaroli L, Aldo P, Alvero AB, Cardenas I, Leirós CP,
et al. Modulation and recruitment of inducible regulatory T cells by
first trimester trophoblast cells. Am J Reprod Immunol. (2012) 67:17–27.
doi: 10.1111/j.1600-0897.2011.01056.x
222. Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human
placental cytotrophoblasts produce the immunosuppressive cytokine
interleukin 10. J Exp Med. (1996) 184:539–48. doi: 10.1084/jem.184.2.539
223. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J,
et al. IL-10 selectively induces HLA-G expression in human trophoblasts and
monocytes. Int Immunol. (1999) 11:803–11.
224. Habicht A, Dada S, Jurewicz M, Fife BT, Yagita H, Azuma M, et al. A link
between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol.
(2007) 179:5211–19. doi: 10.4049/jimmunol.179.8.5211
225. Grozdics E, Berta L, Bajnok A, Veres G, Ilisz I, Klivényi P Jr, et al. B7
costimulation and intracellular indoleamine-2, 3-dioxygenase (IDO)
expression in peripheral blood B7 costimulation and intracellular
indoleamine-2, 3-dioxygenase (IDO) expression in peripheral
Frontiers in Immunology | www.frontiersin.org 20 May 2019 | Volume 10 | Article 911
Jørgensen et al. Tregs in Pregnancy and Cancer
blood of healthy pregnant and non-pregnant women 3-dioxygen.
BMC Pregnancy Childbirth. (2014) 14:1–9. doi: 10.1186/1471-239
3-14-306
226. Zhang Y, Liu Z, Tian M, Hu X, Wang L, Ji J, et al. The altered PD-
1/PD-L1 pathway delivers the ‘one-two punch’ effects to promote the
Treg/Th17 imbalance in pre-eclampsia. Cell Mol Immunol. (2018) 15:710–
23. doi: 10.1038/cmi.2017.70
227. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ,
Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and
function of induced regulatory T cells. J Exp Med. (2009) 206:3015–29.
doi: 10.1084/jem.20090847
228. D’Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, et al.
The link between the PDL1 costimulatory pathway and Th17 in fetomaternal
tolerance. J Immunol. (2011) 187:4530–41. doi: 10.4049/jimmunol.1002031
229. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux
H. Characterization of dendritic cells that induce tolerance and T
regulatory 1 cell differentiation in vivo. Immunity. (2003) 18:605–17.
doi: 10.1016/S1074-7613(03)00113-4
230. Miyazaki S, Tsuda H, Sakai M, Hori S, Sasaki Y, Futatani T, et al.
Predominance of Th2-promoting dendritic cells in early human pregnancy
decidua. J Leukoc Biol. (2003) 74:514–22. doi: 10.1189/jlb.1102566
231. Blois SM, Alba Soto CD, Tometten M, Klapp BF, Margni RA, Arck
PC. Lineage, maturity, and phenotype of uterine murine dendritic cells
throughout gestation indicate a protective role in maintaining pregnancy.
Biol Reprod. (2004) 70:1018–23. doi: 10.1095/biolreprod.103.022640
232. Tiemessen MM, van Herwijnen MJC, Evans HG, Jagger AL, Taams LS, John
S. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of
humanmonocytes/macrophages. Proc Natl Acad Sci USA. (2007) 104:19446–
51. doi: 10.1073/pnas.0706832104
233. Schumacher A, Wafula PO, Teles A, El-Mousleh T, Linzke N,
Zenclussen ML, et al. Blockage of heme oxygenase-1 abrogates the
protective effect of regulatory T cells on murine pregnancy and
promotes the maturation of dendritic cells. PLoS ONE. (2012) 7:e42301.
doi: 10.1371/journal.pone.0042301
234. Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, et al.
Prevention of T cell-driven complement activation and inflammation by
tryptophan catabolism during pregnancy. Nat Immunol. (2001) 2:64–8.
doi: 10.1038/83183
235. Vacca P, Cantoni C, Vitale M, Prato C, Canegallo F, Fenoglio D, et al.
Crosstalk between decidual NK and CD14+myelomonocytic cells results in
induction of Tregs and immunosuppression. Proc Natl Acad Sci USA. (2010)
107:11918–23. doi: 10.1073/pnas.1001749107
236. Moffett A, Colucci F. Uterine NK cells: active regulators at the maternal-fetal
interface. J Clin Invest. (2014) 124:1872–79. doi: 10.1172/JCI68107
237. Moffett-King A. Natural killer cells and pregnancy.Nat Rev Immunol. (2002)
2:656–63. doi: 10.1038/nri886
238. Fukui A, Yokota M, Funamizu A, Nakamua R, Fukuhara R, Yamada K,
et al. Changes of NK cells in preeclampsia. Am J Reprod Immunol. (2012)
67:278–86. doi: 10.1111/j.1600-0897.2012.01120.x
239. Katano K, Suzuki S, Ozaki Y, Suzumori N, Kitaori T, Sugiura-Ogasawara
M. Peripheral natural killer cell activity as a predictor of recurrent
pregnancy loss: a large cohort study. Fertil Steril. (2013) 100:1629–34.
doi: 10.1016/j.fertnstert.2013.07.1996
240. Terme M, Chaput N, Combadiere B, Ma A, Ohteki T, Zitvogel L. Regulatory
T cells control dendritic cell/NK cell cross-talk in lymph nodes at the
steady state by inhibiting CD4+ self-reactive T cells. J Immunol. (2008)
180:4679–86. doi: 10.4049/jimmunol.180.7.4679
241. Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, et al.
CD4 CD25 regulatory T cells inhibit natural killer cell functions in a
transforming growth factor-dependentmanner. J ExpMed. (2005) 202:1075–
1085. doi: 10.1084/jem.20051511
242. Keskin DB, Allan DSJ, Rybalov B, Andzelm MM, Stern JNH, Kopcow HD,
et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells
into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad
Sci USA. (2007) 104:3378–83. doi: 10.1073/pnas.0611098104
243. Fu B, Li X, Sun R, Tong X, Ling B, Tian Z, et al. Natural killer cells
promote immune tolerance by regulating inflammatory TH17 cells at the
human maternal-fetal interface. Proc Natl Acad Sci USA. (2013) 110:E231–
40. doi: 10.1073/pnas.1206322110
244. Renaud SJ, Cotechini T, Quirt JS, Macdonald-Goodfellow SK, Othman M,
Graham CH. Spontaneous pregnancy loss mediated by abnormal maternal
inflammation in rats is linked to deficient uteroplacental perfusion. J
Immunol. (2011) 186:1799–808. doi: 10.4049/jimmunol.1002679
245. Heitmann RJ, Weitzel RP, Feng Y, Segars JH, Tisdale JF, Wolff EF. Maternal
T regulatory cell depletion impairs embryo implantation which can be
corrected with adoptive T regulatory cell transfer. Reprod Sci. (2017)
24:1014–24. doi: 10.1177/1933719116675054
246. Wilczynski JR, Kalinka J, Radwan M. The role of T-regulatory cells
in pregnancy and cancer. Front Biosci. (2008) 13:2275–89. doi: 10.274
1/2841
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Jørgensen, Persson and Hviid. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 21 May 2019 | Volume 10 | Article 911
